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Abstract 
The ErbB signaling network comprises a complex dynamic system, which regulates a 
diverse set of cellular behaviors. In this thesis, we examined how regulating the 
distribution of ErbB receptors between the plasma membrane and different 
endosomal compartments enables contextual regulation of receptor activity and 
signaling. 
In the first part of this work, we investigated how spatial regulation of EGFR controls 
its autocatalytic activity. We found that autonomously activated and EGF activated 
receptors are processed differently by the endocytic machinery. Constitutive vesicular 
recycling through perinuclear areas with high PTP1B phosphatase activity 
suppresses autonomous receptor activation in the absence of ligand, while 
maintaining EGFR abundance at the PM. In contrast, EGF binding enhances EGFR 
self-association and phosphorylation of the c-Cbl docking tyrosine Y1045, which 
results in receptor ubiquitination, internalization and lysosomal degradation. The 
coupling of EGFR self-association state, ubiquitination and vesicular dynamics 
thereby allows for the coexistence of a continuous safeguard cycle, while maintaining 
sensitivity to growth factor stimulation. 
In the second part of this work, we examined how ligand-specific ErbB receptor 
trafficking determines Erk signaling dynamics and localization. We found that EGF or 
heregulin (HRG) differentially modulate ErbB receptor trafficking to generate distinct 
spatiotemporal patterns of receptor activities, leading to the activation of Erk from 
different subcellular compartments (plasma membrane and endosomes). The 
subcellular localization of Erk activation influences its interaction with different 
effector proteins and thereby generates ligand-specific cellular responses. 
Proliferative Erk signals are transmitted to the nucleus, irrespective of their spatial 
origin, while the Erk dependent phosphorylation of pro-migratory effectors relies on 
membrane proximal Erk activity. 
Collectively our findings highlight how vesicular dynamics enable context dependent 
spatial regulation of ErbB activity and downstream signaling events. 
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Zusammenfassung 
Das ErbB-Rezeptor Signalnetzwerk umfasst ein komplexes dynamisches System, 
welches vielfältige zelluläre Verhaltensweisen reguliert. Im Rahmen dieser Arbeit 
wurde untersucht, wie die Regulation der Verteilung von ErbB-Rezeptoren zwischen 
der Plasmamembran und verschiedenen endosomalen Kompartimenten, eine 
kontextabhägige Regulation der Rezeptoraktivität und Signalweiterleitung, 
ermöglicht. Im ersten Teil dieser Arbeit wurde untersucht, wie die räumliche 
Regulation von EGFR seine autokatalytische Aktivität steuert. Es wurde gezeigt, 
dass autonom aktivierte und EGF-aktivierte Rezeptoren unterschiedlich durch die 
endozytische Maschinerie transportiert werden. Konstitutives vesikuläres Recycling 
durch perinukleäre Bereiche mit hoher PTP1B-Phosphatase-Aktivität unterdrückt 
autonome Rezeptoraktivierung in Abwesenheit von Liganden, bei gleichzeitiger 
Aufrechterhaltung der Membranlokalisation von EGFR. Im Gegensatz dazu verstärkt 
die Bindung von EGF die EGFR-Selbstassoziation und Phosphorylierung der c-Cbl-
Bindestelle Y1045, was zur Ubiquitinierung, Internalisierung und zum lysosomalem 
Abbau des Rezeptors führt. Die Kopplung des EGFR-Selbstassoziationszustands, 
der Rezeptor-Ubiquitinierung und der vesikulären Dynamik, ermöglicht somit die 
Koexistenz eines kontinuierlichen, suppressiven vesikuläreren Transportkreislaufes, 
während die Empfindlichkeit für die Stimulierung mit Wachstumsfaktoren erhalten 
bleibt. Im zweiten Teil dieser Arbeit wurde untersucht, wie der Liganden-spezifische 
ErbB-Rezeptor Transport die raumzeitliche Organisation der Erk-Signalgebung 
steuert. Es wurde gezeigt, dass EGF oder Heregulin (HRG) den ErbB-Rezeptor 
Transport unterschiedlich modulieren und so unterschiedliche raumzeitliche Muster 
von Rezeptoraktivitäten erzeugen. Dies führt zur Aktivierung von Erk aus 
verschiedenen subzellulären Kompartimenten (Plasmamembran und Endosomen). 
Die subzelluläre Lokalisation der Erk-Aktivierung beeinflusst die Interaktion von Erk 
mit verschiedenen Effektorproteinen und erzeugt dadurch unterschiedliche zelluläre 
Antworten. Proliferative Erk-Signale werden unabhängig von ihrem räumlichen 
Ursprung an den Zellkern übertragen, während die Erk-abhängige Phosphorylierung 
pro-migratorischer Effektoren auf membrannaher Erk-Aktivität beruht. 
Zusammenfassend zeigen unsere Ergebnisse, wie die Regulation der vesikulären 
Dynamik von ErbB-Rezeptoren eine kontextabhängige räumliche Regulation ihrer 
Aktivität und Signalweiterleitung ermöglicht.  
 10 
1 Introduction 
Cells are constantly exposed to a wide range of extracellular cues and growth factors 
which they need to sense and interpret. The ability of cells to adapt their behaviour 
with regard to their environment is an essential aspect of tissue development and 
homeostasis1,2. Cells use signalling networks to process extracellular information and 
translate these into distinct responses (e.g. proliferation, differentiation, movement or 
death)3. These signalling networks are highly dynamic, often reconfigurable and can 
generate context-dependent function, instead of being static, linear and hardwired4–6. 
Although the identity of numerous central components of many signaling pathways 
has been determined and ample studies have addressed their inherent molecular 
properties, how they collectively process information to generate a defined cellular 
response to extracellular signals is still poorly understood. A growing number of 
studies supports that cells send and receive information about their environment by 
controlling the spatial and temporal dynamics of signaling molecules7–10. A systems 
level understanding how different stimuli can be encoded in spatial and temporal 
patterns and how these dynamics are interpreted and shape cellular behaviour could 
provide new insights into how cells generate higher-order emergent behavior and 
may reveal new pharmacological strategies for the treatment of disease11,12.  
1.1 ErbB receptors 
Cell surface receptors function as sensory organs, which enable cells to sense their 
environment and convert extracellular signals into intracellular signaling events, 
employing a plethora of different posttranslational modifications13. Mechanisms that 
regulate the spatial and temporal activity of these receptors can influence their 
sensitivity to stimuli, duration of activity and bias their interactions with effectors, 
providing different levels of regulation that can influence the cellular response to 
receptor activation. Based on their structure, cell surface receptors are grouped into 
different families. 
The ErbB/HER family of cell surface receptors form a subgroup of receptor tyrosine 
kinases which includes four family members: EGFR (HER1/ErbB1), ErbB2 
(HER2/Neu), ErbB3 (HER3) and ErbB4 (HER4)14. ErbB receptors are ubiquitously 
expressed in epithelial, cardiac, mesenchymal, and neuronal cells and mediate 
fundamental, often opposing cellular responses including proliferation, differentiation, 
migration, survival and/or apoptosis15,16. ErbB receptors consist of an extracellular 
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ligand-binding domain, followed by a single transmembrane helix and an intracellular 
module composed of a juxtamembrane segment, a tyrosine kinase domain and a C-
terminal tail (Fig.1)17. The canonical scheme of ErbB receptor activation relies on 
ligand-induced receptor homo- or heterodimerzation, followed by allosteric activation 
of their intrinsic kinase activity and the phosphorylation of tyrosine residues within the 
C-terminal tail of the receptor which can act as effector docking sites14,17–20. 
Subsequent recruitment of PTB- or SH2-containing effector proteins relays the 
extracellular signal inside the cytoplasm21,22. Notably, the activation of ErbB2 and 
ErbB3 relies on the formation of receptor heterodimers, since for ErbB2 no ligands 
have been identified yet, while ErbB3 is kinase impaired15,23. To date, seven different 
ligands of EGFR have been identified: Epidermal growth factor (EGF), transforming 
growth factor alpha (TGF-α), betacellulin (BTC), heparin-binding EGF-like growth 
factor (HB-EGF), amphiregulin (ARG), epiregulin (EPR), and epigen (EGN). BTC, 
HB-EGF and EPR as well as neuregulins (e.g. heregulins) can also bind and activate 
ErbB4, whereas the latter also binds to ErbB3 and promotes its heterodimerization 
with ErbB216. Individual ligands can induce qualitatively and quantitatively different 
responses of downstream signaling molecules and thereby promote different cellular 
behaviours24. 
 
Figure 1: Domain structure of ErbB receptors. The N-terminal extracellular domain is 
composed of four subdomains (I – IV), which participate in ligand binding and receptor 
dimerization. A single transmembrane (TM) spanning alpha-helix is followed by a juxtamembrane 
segment, the kinase domain and the C-tail containing tyrosine autophosphorylation sites 
(depicted in red), serving as docking sites for the recruitment of downstream signaling 
molecules17. 
Transmembrane helix
Juxtamembrane segment
Kinase domain
C-tail
Extracellular domain
III I
IV
II
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1.2 Epidermal growth factor receptor (EGFR) 
EGFR belongs to the ErbB family of receptor tyrosine kinases. Signaling initiated by 
EGFR is implicated in the regulation of cellular growth, survival, proliferation and 
differentiation and is therefore vital during development and maintenance of tissue 
homeostasis25,26. Since EGFR can elicit potent mitogenic responses, dysregulation of 
its activity due to mutations and/or overexpression has been causally linked to tumor 
development and progression in different of types of cancer27,28. Elevated EGFR 
expression/activity is a hallmark of several cancers and EGFR therefore has 
emerged as an attractive therapeutic target for the use of small molecule or antibody-
based approaches29. EGFR regulates a complex signaling network, increasing the 
activity of many intracellular signaling effectors, including phosphatidylinositol 3-
kinase (PI3K) and its downstream kinase Akt (PKB), the Ras/Raf/Mek/Erk1/2 
signaling cascade and phospholipase C (PLCγ), among others15,30. 
1.3 EGFR structure and activation 
The activation of most RTKs requires trans-autophosphorylation of regulatory 
tyrosine residues in the activation loop, the juxtamembrane segment, and/or the C-
terminal tail14. In contrast, EGFR family members are activated through the allosteric 
interaction between two kinase domains within a receptor dimer and do not rely on 
trans-autophosphorylation events17,19. The extracellular module (ECM) of EGFR is 
composed of four domains, denoted domains 1, 2, 3, 4. The domains 1 and 3 form 
the ligand binding side, while the domains 2 and 4 have regulatory functions31. 
Crystal structures showed that in the absence of ligand the ECM adopts an 
autoinhibited (“tethered’’) conformation through interactions between a β-hairpin of 
domain 2 (dimerization arm) with domain 4 (Fig.1)32. This configuration constrains 
the domains 1 and 3 to a distant orientation, which prevents an EGF molecule to 
contact both domains simultaneously32. Ligand binding results in conformational 
rearrangement and converts the ECM to an extended conformation, releasing the 
dimerization arm and thereby enabling `back-to-back` dimerization with the 
corresponding element of second a receptor molecule (Fig.2)31. On the intracellular 
site the kinase domains of a receptor dimer interact in an asymmetric fashion. One 
kinase domain (termed “activator”) allosterically locks the second kinase domain 
(termed “receiver”) in an activated conformation (Fig.2)19. This involves interactions 
between the αH helix in the C-lobe of the activator kinase and the αC helix in the N-
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lobe of the receiver kinase, causing a switch from the “αC-out inactive’’ conformation 
to an “αC-in active’’ conformation33,34. This configuration enables the formation of a 
catalytically important salt bridge between Lys721 and Glu738, to co-ordinate the α- 
and β-phosphates of ATP bound to the active site and thereby allows the activated 
receiver kinase to phosphorylate the C-tail of the activator kinase35. Structural 
coupling between the extracellular and intracellular module further enables specific 
interactions between the trans- and juxtamembrane segments of a receptor dimer 
required for the formation of an asymmetric kinase dimer36,37. In particular, ligand 
binding removes steric constraints in the ECM and allows the transmembrane 
segments to associate through their N-terminal GxxxG dimerization motifs. This 
configuration promotes membrane release of the intracellular module from the 
plasma membrane and allows the formation of an antiparallel dimer between the N-
terminal residues of the juxtamembrane segment (JM-A Segment)38. In addition, the 
C-terminal half of the juxtamembrane segment (JM-B segment) of the receiver kinase 
forms a latch along the C-lobe of the activator kinase and thereby further stabilizes 
the asymmetric kinase dimer38. Notably, ligand binding to EGFR has also been 
reported to generate higher-order multimers, which have been suggested to 
cooperatively enhance auto-phosphorylation in trans between neighboring 
dimers39,40. 
 
Figure 2: Ligand-induced dimerization and allosteric activation of EGFR. Ligand binding 
(e.g. EGF) to the extracellular domain of EGFR promotes receptor dimerization, the formation of 
an asymmetric kinase dimer and subsequent trans-autophosphorylation of the C-tail of activator 
kinase via the allosterically activated receiver kinase (adapted from 38). 
1.4 Autonomous EGFR activation 
EGFR dimerization, which enables allosteric activation of its intrinsic kinase activity 
and triggers trans-autophosphorylation is primarily driven by the binding of growth 
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factors to the ECM of the receptor. However, due to thermal fluctuations ligandless 
EGFR can also attain an active conformation and, via the formation of short-lived 
dimers, trigger spontaneous autonomous phosphorylation events14,41,42. Moreover, it 
has been suggested that phosphorylation of tyrosine 845 within the activation loop 
establishes an autocatalytic feedback by stabilizing the active conformation of the 
receptor and thus triggering autonomous ligand-independent signal propagation43. In 
accordance with this, previous studies showed that local EGF stimulation promoted 
lateral propagation of EGFR activation at high EGFR expression levels44,45. Growth 
factor stimulation further promotes the recruitment and activation of reactive oxygen 
species (ROS) producing enzyme systems such as NADPH oxidase to the plasma 
membrane46–48. Due to their short half live time, the presence of ROS remains 
spatially constrained to the plasma membrane. Local ROS production transiently 
inhibits inhibitory protein tyrosine phosphatases (PTP), through reversible oxidation 
of a catalytic cysteine residue, and thereby lowers the activation threshold of 
neighbouring receptors41,49. Coupling of EGFR activation with PTP inhibition at the 
plasma membrane thereby exemplifies a double-negative feedback loop, which 
together with the autocatalytic kinase activity, establishes a bistable reaction network 
with switch like response properties41,46. Analogous to a toggle switch, this reaction 
network converts growth factor stimuli into threshold-activated responses41,50. 
However, the autocatalytic kinase activity also amplifies spurious receptor activation 
in the absence of growth factor stimuli, necessitating additional regulatory 
mechanisms to control EGFR activity in the presence and absence of growth factors. 
1.5 Structural auto-inhibitory features of EGFR 
The activity of EGFR and its phosphorylation dynamics are regulated via different 
intrinsic structural features and extrinsic cellular regulatory machineries. Multiple 
auto-inhibitory structural mechanisms create an energy barrier for EGFR self-
association and thereby antagonize its activation in the absence of growth factors. 
Recent NMR and molecular dynamics simulations showed that in the ligand-free 
state the ECM is highly dynamic and forms an ensemble of different conformations, 
but generally adopts compact conformations over the extended conformation37,51. In 
ligand-free receptor dimers, the compact configuration of the ECM favors C-terminal 
over N-terminal dimerization of the transmembrane helices, dissociation and 
membrane burial of the juxtamembrane segments and the formation of symmetric, 
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inactive kinase dimers37. In addition, tethering of the intracellular module through 
electrostatic interactions between the negatively charged plasma membrane and 
positively charged patches obstruct the active site of the kinase domain37. The 
dimerization of two kinase domains is further hindered through local intrinsic disorder 
of the αC-helix region34. Activation loop phosphorylation of Tyr845 or the L834R 
mutation often found in lung cancer suppresses the disordered state, thereby 
enhancing receptor dimerization affinity, and suggesting a potential mechanism for 
autonomous, ligand-independent signal propagation34. The C-tail of EGFR has 
further been shown to form autoinhibitory interactions which interfere with the 
formation of an asymmetric kinase dimer31,38. 
In addition to these intrinsic auto-inhibitory mechanisms, the endocytic machinery 
and protein tyrosine phosphatases (PTP) comprise extrinsic regulatory layers of 
EGFR activity46,52. 
1.6 Protein tyrosine phosphatases (PTP) 
The spatially distributed superfamily of cysteine-based PTPs regulates EGFR 
phosphorylation dynamics though the removal of phosphate groups from tyrosine 
residues. The overall level of EGFR phosphorylation is the product of a continuous 
and rapid cycle of phosphorylation and de-phosphorylation events46,53. Pan-specific 
PTP inhibition using the thiol reactive compound pervanadate has been shown to 
cause rapid EGFR phosphorylation in the absence of ligand, demonstrating the 
critical opposing role of PTPs to suppress ligand-independent EGFR activation54,55. 
Since the catalytic activity of certain PTPs (e.g. PTP1B and TCPTP) exceeds EGFR 
kinase activity by up to two orders of magnitude, spatial regulation of their activity is a 
prerequisite to permit EGFR phosphorylation56–58. Previous studies showed a PTP1B 
activity gradient emanating from the perinuclear area and declining towards the 
plasma membrane59. The relatively low membrane-proximal PTP activity has been 
suggested to be sufficient to shift the kinase-phosphatase balance in favor of the 
phosphatase in the absence of growth factor stimulation, while ligand binding shifts it 
in favor of the kinase46. 
1.7 Endocytic trafficking of EGFR  
The spatial localization of signaling molecules is a critical parameter determining their 
response properties and functional output. The endocytic machinery is composed of 
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functionally distinct intracellular membrane compartments and regulates the 
internalization, re-localization and fate (i.e. endosomal-plasma membrane recycling 
versus lysosomal degradation) of signaling molecules from the plasma membrane. 
Members of the Rab small GTPase family act as multifaceted organizers of vesicular 
trafficking and control vesicular biogenesis, budding, delivery and fusion by the 
coordinated recruitment of various effector proteins60. Through hydrophobic 
geranylgeranyl groups, different Rab proteins are localized to distinct intracellular 
membranes and/or microdomains, organizing a modular system in which each Rab 
protein performs different functions (Fig.3)61. Rab5 participates during early stages of 
the endocytic pathway and mediates cargo entry and fusion of primary endocytic 
vesicles to form early endosomes (EE)62. The fate of endocytic cargo is determined 
by sorting events to subsequent endosomal compartments. Endosomal maturation 
from EE to late endosomes (LE) involves the replacement of Rab5 with Rab7, which 
mediates fusion of LE and/or multivesicular bodies with lysosomes61,63. In contrast, 
recycling of internalized cargo to the plasma membrane occurs via two routes: Rab4-
mediated recycling directly from the EE to the plasma membrane or via Rab11-
positive vesicles which mediate recycling through perinuclear recycling endosomes 
(RE, Fig3)64,65. Vesicular membrane dynamics enable different contextual modes of 
EGFR regulation by modulating its spatial distribution between the plasma membrane 
and different endosomal compartments66,67. The balance between internalization and 
recycling determines the density of EGFR at the plasma membrane. In the absence 
of ligand, EGFR is continuously internalized and recycled back to the plasma 
membrane, maintaining a steady state spatial distribution with the majority of EGFR 
located at the plasma membrane68,69. In contrast, ligand binding enhances EGFR 
internalization, resulting in its endosomal accumulation (Fig.3)67. Internalization of 
ligand-activated receptors extends the axial reach and the duration of plasma 
membrane initiated signaling events throughout the cytoplasm and can further create 
reaction platforms with distinct signaling repertoires46,70. Depending on the cellular 
context and ligand concentration, EGFR can be internalized through clathrin-
mediated endocytosis (CME) or several other mechanisms (globally referred to as 
non-clathrin endocytosis, NCE)71. Internalization via CME in the absence or at low-to-
intermediate ligand concentrations mainly results in receptor recycling to plasma 
membrane, thereby extending the duration of its signaling capacities72. In contrast, 
high ligand concentrations trigger NCE pathways and promote receptor 
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ubiquitination, which targets the receptor for lysosomal degradation73. Ubiquitination 
of EGFR is mediated by members of the of the Cbl family of E3-ubiquitin-ligases that 
interact either directly with a phosphorylated tyrosine residue (pY1045) or indirectly 
through the adaptor protein Grb2, which binds to pY1068 and pY108674–76. 
Endocytosis of ligand bound receptors has further been shown to enable interaction 
of EGFR and the ER-bound phosphatase PTP1B, thereby contributing to the 
termination of receptor activity77,78. 
 
Figure 3: Vesicular dynamics of EGFR. EGF stimulation promotes EGFR internalization via 
Rab5-positive endosomes. Internalized EGFR is either recycled back to the plasma membrane 
via the peripheral or perinuclear recycling endosomes or trafficked to the lysosome for 
degradation. Rab GTPases localized to distinct intracellular membranes and/or microdomains are 
indicated by colors. 
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1.8 Mitogen activated protein kinases (MAPK) 
Phosphorylated tyrosine residues within the C-tail of EGFR recruit a variety of 
signaling molecules such as Shc or Grb2, which trigger the activation of various 
signal-transducing proteins15,79–81. Among these, extracellular regulated kinase 1/2 
(Erk1/2) functions as an important regulator to integrate external cues into 
intracellular signalling events. Erk belongs to the evolutionary conserved superfamily 
of mitogen activated protein kinases (MAPKs), which mediate numerous cellular 
responses including cellular proliferation, differentiation, and survival82. MAPKs form 
three-tiered modules, which are activated by sequential phosphorylation events: a 
MAPK kinase kinase (MAPKKK) phosphorylates a MAPK kinase (MAPKK), which in 
turn activates a MAPK83 (Fig.4). So far six different MAPK modules have been 
identified in mammalian cells: Erk1/2, Erk3/4, Erk5, Erk7/8, Jun N-terminal kinase 
(JNK) and the p38 isoforms α/β/γ(ERK6)/δ84,85. Activated MAPKs function as proline 
(P) directed serine/threonine (S/T) selective protein kinases which phosphorylate a 
plethora of substrate proteins on selected S/T residues followed by P and thereby 
regulate numerous cellular responses85,86. This process is further thought to be 
mediated via docking interactions that occur outside of the active site between 
MAPKs and their substrates87. Dysregulation of MAPK activity has been implicated in 
various forms of human disease and developmental disorders88–90. 
 
Figure 4: Scheme of the three-tiered MAPK module in eukaryotic cells. External signals 
sensed by growth factor receptors induce the sequential phosphorylation and activation of the 
three MAPKs (MAPKKK, MAPKK and MAPK), with the terminal MAPK directing the cellular 
response83. 
MAPKKK
MAPKK
MAPK
MAPK module
Cellular response
Extracellular stimulus
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1.9 Extracellular regulated kinase (Erk) 
The Erk1/2 MAPK-module further involves the MAPKKK Raf and the MAPKK 
Mek1/2. Activation of this module is frequently initiated via Ras-family GTPases91. 
Plasma membrane activated growth factor receptors promote Ras activation via 
recruitment of the Ras-guanine nucleotide exchange factor (GEF) son-of-sevenless 
(SOS), which promotes the GDP to GTP exchange of Ras proteins92. Activated 
RasGTP in turn serves as a reactivity-enhancing recruitment factor which 
concentrates effector proteins such as Raf at the plasma membrane (Fig.5)93. 
Recruitment of Raf family kinases (A-, B-, and C-Raf) to the plasma membrane 
enables their allosteric activation via homo- or heterodimerization94. Activated Raf 
kinases further promote the phosphorylation and activation of Mek1/2, which then 
activate Erk1/2 via phosphorylation of threonine and tyrosine residues within their 
activation loop (Thr202/Tyr204 for Erk1 and Thr185/Tyr187 for Erk2)95,96. 
Dephosphorylation and thereby inactivation of Erk is catalysed by dual-specificity 
phosphatases (DUSPs), that can dephosphorylate both tyrosine or serine/threonine 
residues97. Erk is known to interact with over 170 proteins, including many substrates 
and regulators98. These interactions are further facilitated by two distinct docking 
domains: a common docking (CD/ED) domain which interacts with D site motifs (also 
called DEJL motifs), and a F Recruitment Site (FRS), which interacts with an FXF 
(DEF) motif on substrate proteins96. In resting cells, Erk is primarily located in the 
cytoplasm due to interactions with anchoring proteins; however, upon activation Erk 
can translocate to the nucleus where it promotes gene expression and DNA 
replication99. Different growth factors are thought to promote distinct cellular 
responses through dynamic changes of Erk interaction partners100. Different 
mechanisms have been suggested to cooperatively direct Erk signals to different 
downstream targets, including the duration and signal strength of Erk activation, its 
interaction with scaffold proteins, spatial compartmentalization, and crosstalk with 
other signalling molecules (Fig.6)101. Aberrant regulation of Erk activity further 
contributes to various forms of cancer and other human diseases, most commonly 
due to mutations in EGFR, RAS, BRAF, CRAF, or MEK1/2102. 
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Figure 5: EGFR mediated Erk activation at the plasma membrane. EGF induced activation of 
EGFR induces the recruitment of a GEF complex (Grb2-SOS) to the plasma membrane to 
activate the membrane-bound GTPase Ras to recruit Raf to the plasma membrane. Raf promotes 
Mek phosphorylation, which subsequently catalyzes Erk phosphorylation. Activated Erk 
phosphorylates various cytosolic effectors and also translocates to the nucleus, where it 
phosphorylates different transcription factors to regulate gene expression92. 
1.10 Regulation of Erk signaling specificity 
Given its ubiquitous role during numerous different and even opposing cellular 
responses, Erk acts as multifunctional signalling hub, which receives and integrates 
inputs from various stimuli. This functional plasticity represents a conundrum in 
regard to how the promiscuous activation of a shared signalling molecule can 
generate a specific cellular response to a given stimulus. The spatial and temporal 
organization of Erk activity are considered mechanisms that can encode variable 
extracellular signals into distinct cellular responses (Fig.6A, C)101,103,104. Different 
growth factors have been shown to induce distinct temporal patterns of Erk 
activation, which have been linked to different cellular fates105. Network motifs such 
as feed-forward loops allow decoding of Erk signal duration and thereby the induction 
of specific gene expression patterns that drive different cellular responses106–108. 
Furthermore, recent studies using constitutively active Ras mutants artificially 
targeted to specific subcellular locations established that the subcellular localization 
of Erk activation can influence its substrate pool104,109,110. Since Erk interacts with a 
plethora of substrate and effector proteins, the context-dependent formation of 
different protein complexes can further specify cellular responses100. Differences in 
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the spatial and temporal dynamics of Erk activity are determined by the underlying 
causal interactions within the MAPK signalling network (Fig.6D)3. The topology of the 
network depends on the cellular context and the resulting dynamics of Erk govern the 
cellular response. In PC12 cells, for example, the signal-dependent wiring of causal 
interactions within the network has been shown to result in different temporal Erk 
dynamics which determine cellular fate: proliferation (EGF, transient Erk response) 
and differentiation (NGF, sustained Erk response, Fig.6A)4. In this regard, it has 
been demonstrated that cellular responses can be rewired through targeted 
perturbation of causal interactions governing Erk dynamics4. 
 
Figure 6: Mechanisms determining Erk signaling specificity and signaling dynamics. (A) 
Duration and strength of Erk activation. (B) Assembling the molecular components on scaffold proteins 
can facilitate their interaction and further provide positive (green arrow) and negative (red arrow) 
mechanisms of regulation, tuning the response dynamics. (C) The subcellular localization of Erk 
(nucleus or cytoplasm) can promote different cellular responses. (D) Crosstalk and conditional causal 
interactions can manifest in different dynamics of Erk activity3,9,111,112. 
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2 Objectives 
Vesicular trafficking allows the cell to dynamically regulate the spatial distribution of 
ErbB receptors between the plasma membrane (PM) and different endosomal 
compartments, however the signaling repertoire of endosomal and plasma 
membrane localized receptors can differ if biochemical components of the signal 
transduction machinery are not equally accessible within the different compartments. 
Changes in vesicular trafficking dynamics can alter the spatial distribution of ErbB 
receptors and therefore form an important layer of regulation of receptor activity and 
signaling that could enable context-dependent regulation. The ensuing study is 
divided into two parts, addressing the following questions: 
Autocatalytic amplification of ligand-induced EGFR activation coupled to local PTP 
inhibition establishes a bistable reaction network with switch like response properties. 
While this feature ensures robust receptor activation to extracellular signals, it also 
creates the potential to amplify spontaneous phosphorylation events in the absence 
of growth factors41,46. Thus, the question arises of how the cell suppresses 
uncontrolled autonomous EGFR activation, while maintaining responsiveness to 
ligand stimulation. Endocytosis of ligand-activated EGFR has been shown to promote 
its interaction with spatially distributed PTPs to suppress its activity78. In this thesis, 
the role of EGFR vesicular dynamics in the regulation of autonomous receptor activity 
will be examined, as well as how endosomal trafficking differentially controls the 
activity of autonomously and ligand-activated EGFR. 
Intriguingly, different ErbB ligands can induce distinct cell fates within a single cell 
type, despite the promiscuous activation of shared signal transducing proteins, such 
as the Ras/Erk mitogen-activated protein kinase (MAPK) cascade. In this regard, it 
has been suggested that dynamic changes in Erk-interacting proteins represent a 
key mechanism specifying the cellular response. Although receptor endocytosis 
attenuates receptor activation and signaling at the plasma membrane, active EGFR 
can continue to signal from endosomes. The second part of this thesis will examine 
how differences in the spatial and temporal distribution of active ErbB receptors 
within the endosomal system influence the subcellular localization of Erk activity, 
thereby modulating its interaction with different pools of substrates to generate 
specific cellular responses.  
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3 Material and Methods 
3.1 Materials 
3.1.1 Chemicals and Reagents 
2-Mercapto-ethanol     SERVA Electrophoresis GmbH 
2’-deoxyadenosine-5’-triphosphate (dATP) InvitrogenTM Life Technologies 
2’-deoxycytidine-5’-triphosphate (dCTP) InvitrogenTM Life Technologies 
2’-deoxyguanosine-5’-triphosphate (dGTP) InvitrogenTM Life Technologies 
2’-deoxythymidine-5’-triphosphate (dTTP) InvitrogenTM Life Technologies 
40 % (29:1)      Carl Roth GmbH 
Ammonium persulfate (APS)    SERVA Electrophoresis GmbH 
Ampicillin sodium salt     SERVA Electrophoresis GmbH 
Bromophenolblue      Sigma-Aldrich® 
Cell Lysis buffer, 10x    Cell Signaling Technology 
Cocktail Tablets     Roche 
cOmplete, Mini, EDTA-free Protease Inhibitor   
Dimethyl sulfoxide (DMSO)    SERVA Electrophoresis GmbH 
Dithiothreitol (DTT)      Fluka® Analytical 
Epidermal growth factor (EGF)   Sigma-Aldrich® 
Erlotinib      Selleckchem 
Ethanol      J.T.Baker 
Ethylenediaminetetracetic acid (EDTA)   Fluka® Analytical 
Glycerol       GERBU Biotechnik GmbH 
Glycine      Carl Roth GmbH 
Heregulin-β3      Millipore, Merck KGaA 
Histofix      Carl Roth GmbH 
Hydrogenperoxid (H2O2)    Merck 
Isopropanol      J.T.Baker 
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Kanamycin sulfate      GERBU Biotechnik GmbH 
Lapatinib      Selleckchem 
Magnesium chloride (MgCl2)    Merck KG/J.T.Baker 
Methanol       AppliChem GmbH 
N,N,N’,N’-Tetramethylene-diamine (TEMED)  Sigma-Aldrich® 
PD0325901      Selleckchem 
Phosphatase Inhibitor Cocktail 2    Sigma-Aldrich® 
Phosphatase Inhibitor Cocktail 3    Sigma-Aldrich® 
Poly-L-Lysine     Sigma-Aldrich® 
RedSafe, DNA Stain     Chembio Ltd, Hertfordshire, UK 
Rotiphorese® NF-acrylamide/bis-solution  
Sodium chloride (NaCl)    Fluka® Analytical 
Sodium dodecyl sulfate (SDS)   SERVA Electrophoresis GmbH 
sodium orthovanadate    Sigma-Aldrich® 
Tris-base       Carl Roth GmbH 
Tris-HCl       J.T.Baker 
Triton X-100       SERVA Electrophoresis GmbH 
Tween 20       SERVA Electrophoresis GmbH 
UltraPureTM Agarose    InvitrogenTM Life Technologies 
3.1.2 Commercial Solutions 
100 mM dNTP mix      InvitrogenTM Life Technologies 
100x BSA       New England Biolabs Inc. 
10x Lysis Buffer     Cell Signaling Technology 
2-log DNA ladder     New England Biolabs Inc. 
50 mM Magnesium Sulfate    InvitrogenTM Life Technologies 
5x T4 DNA Ligation Buffer    InvitrogenTM Life Technologies 
blocking buffer     LI-COR Biosciences GmbH 
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CutSmart™ Buffer     New England Biolabs Inc. 
DPBS       PANTM Biotech GmbH 
Dulbecco’s Modified Eagle’s Medium (DMEM)  PANTM Biotech GmbH 
Fetal calf serum (FCS)     PANTM Biotech GmbH 
Fugene® 6 transfection reagent    Roche Applied Science 
Imaging medium     PANTM Biotech GmbH 
L-Glutamine       GIBCO®/InvitrogenTM 
LipofectamineTM 2000.     InvitrogenTM 
Odyssey Infrared Imaging System 
Precision Plus ProteinTM standards   Bio-Rad Laboratories, Inc. 
T4 DNA ligase reaction buffer, 10×  New England BioLabs 
3.1.3 Buffers and Media 
LB medium    10 g/l Bacto-Trypton, 5 g/l bacto-yeast extract,  
10 g/l NaCl and finally autoclave 
LB agar plates add 15 g agar per litre LB medium, pour plates when the 
autoclaved medium has approximately 55 °C, add 
antibiotic of choice at desired concentration 
SOC medium  20 g/l Bacto-Trypton, 5 g/l bacto-yeast extract, 0.5 g/l 
NaCl, 2.5 mM KCl, 10 mM MgCl2 (SOB medium), 
autoclave and before usage add 20 mM glucose to obtain 
SOC 
1x PBS (pH 7.4)  138 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl, 1.8 mM 
KH2PO4 
5x SDS sample buffer  60 mM Tris-HCl (pH 6.8), 25 % glycerol, 2 % SDS, 14.4 
mM 2-mercapto-ethanol, 0.1 % bromo-phenolblue 
SDS running buffer  25 mM Tris-base, 192 mM glycine, 0.1 % SDS 
Separating gel buffer  1 M Tris-HCl (pH 8.8) 
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Stacking gel buffer   0.375 M Tris-HCl (pH 6.8) 
1x TAE buffer  40 mM Tris/Acetate (pH 7.5), 20 mM NaOAc, 1 mM EDTA 
1x TBS    100 mM Tris-HCl (pH 7.4), 150 mM NaCl 
1x TBST  100 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1 % (v/v) 
Tween 
Transfer buffer   25 mM Tris-base, 192 mM glycine, 20 % (v/v) methanol. 
Modified RIPA buffer 50  mM Tris–HCl, 150  mM NaCl, 1  mM EDTA, 1  mM 
EDTA, 1 % Triton X-100, 1 % sodium deoxycholate, 1 % 
SDS 
3.1.4 Bacterial Strains 
XL10 Gold    Stratagene (regrown in-house) 
3.1.5 Enzymes 
Calf Intestinal Phosphatase (10,000 U/ml)   New England Biolabs Inc. 
High-Fidelity (HF®) Restriction Endonucleases  New England Biolabs Inc. 
PlasmidSafe ATP-dependent DNase   Epicentre 
Q5® High-Fidelity DNA Polymerase   New England Biolabs Inc. 
T4-DNA ligase      InvitrogenTM Life Technologies 
3.1.6 Kits 
High Pure endotoxin-freeNucleoBond®    
Micro BCA™ Protein Assay Kit    Thermo Scientific 
Q5® Site-Directed Mutagenesis Kit   New England Biolabs Inc. 
Roti®-Prep Plasmid MINI     Carl Roth GmbH 
SiiR-DNA kit       Spirochrome 
Xtra Midi EF       MACHEREY-NAGEL 
Zymoclean™ Gel DNA Recovery Kit    Zymo Research 
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3.1.7 Antibodies 
Primary antibodies 
tRFP (AB234)      Evrogen 
Akt (pan) (2920)      Cell Signaling Technology 
anti-EGF Receptor (pY845) (558381)   BD Biosciences 
c-Fos (9F6) (2250)      Cell Signaling Technology 
Cbl Antibody (C-15) (SC-170)    Santa Cruz Biotechnology 
Cyclin D1 (92G2) (2978)     Cell Signaling Technology 
EGF Receptor (D38B1) (4267)    Cell Signaling Technology 
EGFR/ErbB1 (AF231)     R&D Systems 
EphA2 (AF-3035)      R&D Systems 
ErbB-3 (C-17) (sc-285)     Santa Cruz Biotechnology 
ErbB2 (9G6) (sc-08)     Santa Cruz Biotechnology 
Erk1/2 (L34F12) (4696)     Cell Signaling Technology 
Erk1/2 [9B3] (ab36991)     Abcam 
GAPDH (6C5) (CB1001)     Calbiochem, Merck 
HA-antibody (MMS-101P)     Covance Inc. 
HER2/ErbB2 (29D8) (2165)    Cell Signaling Technology 
HER4/ErbB4 (111B2) (4795)    Cell Signaling Technology 
KSR1 [EPR2421Y] (ab68483)    Abcam 
KSR2 (K75) (sc-100421)      Santa Cruz Biotechnology 
Living colors® GFP AB (632381)    Clontech 
Living colors® GFP AB (632593)    Clontech 
Paxillin (610051)      BD Biosciences 
Phospho- Erk1/2 (Thr202/Tyr204) (4370)  Cell Signaling Technology 
Phospho- Erk1/2 (Thr202/Tyr204) (9101)  Cell Signaling Technology 
Phospho-Akt (Ser473) (9271)    Cell Signaling Technology 
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Phospho-EGF Receptor (Tyr1068) (2234)  Cell Signaling Technology 
Phospho-EGFR (Tyr1045) (2237)   Cell Signaling Technology 
Phospho-EGFR (Tyr845) (558381)   BD Biosciences 
Phospho-EGFR(Tyr1068) (D7A5) (3777)  Cell Signaling Technology 
Phospho-EphA2 (Ser897) (D9A1) (6347)  Cell Signaling Technology 
Phospho-HER2/ErbB2 (Tyr1221/1222)    Santa Cruz Biotechnology 
Phospho-HER3/ErbB3 (Tyr1289) (21D3) (4791) Cell Signaling Technology 
Phospho-Rb (Ser807/811) (D20B12) (8516)  Cell Signaling Technology 
Rab11 Antibody (3539)     Cell Signaling Technology 
Rab11A (ab65200)      Abcam 
Rab11a Antibody (2413)     Cell Signaling Technology 
WAVE2 (3659)      Cell Signaling Technology 
α-Tubulin (T6074)      Sigma Aldrich 
Secondary antibodies for Western blots and In Cell Western 
IRDye 680 donkey anti-mouse IgG    LI-COR Biosciences 
IRDye 800 donkey anti-rabbit IgG   LI-COR Biosciences 
IRDye 800 donkey anti-mouse IgG    LI-COR Biosciences 
IRDye 680 donkey anti-rabbit IgG   LI-COR Biosciences 
IRDye 680 donkey anti-goat IgG    LI-COR Biosciences 
Secondary antibodies for immunofluorescence 
Alexa Fluor® 647 chicken anti-rabbit IgG  Life Technologies 
Alexa Fluor® 647 donkey anti-mouse IgG  Life Technologies 
Alexa Fluor® 555 donkey anti-goat IgG   Life Technologies 
Alexa Fluor® 488 donkey anti-mouse IgG  Life Technologies 
Alexa Fluor® 546 goat anti- rabbit IgG   Life Technologies 
Alexa Fluor® 546 goat anti-mouse IgG    Life Technologies 
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3.1.8 Oligonucleotides 
siRNA 
Rab11a 5 ́(AATGTCAGACAGACGCGAAAA)-3  ́ Qiagen 
Rab11b 5 ́(AAGCACCTGACCTATGAGAAC)-3  ́ Qiagen 
Control siRNA (1027281)     Qiagen 
Rab11a siRNA (sc-36340)     Santa Cruz Biotechnology 
Control siRNA (sc-37007)     Santa Cruz Biotechnology 
ErbB2 siRNA (L-003126-00-0005)   Dharmacon 
ErbB3 siRNA (L-003127-00-0005)   Dharmacon 
ErbB4siRNA (L-003128-00-0005)   Dharmacon 
DNA 
Desalted DNA-oligonucleotides were purchased from Sigma-Aldrich Chemie GmbH. 
3.1.9 Plasmids 
EGFR-mCitrine Encoding human EGFR with C-terminally 
fused mCitrine 
EGFR-mCherry Encoding human EGFR with C-terminally 
fused mCherry 
EGFR-Y1045F-mCitrine Encoding human EGFR-Y1045F with C-
terminally fused mCitrine 
EGFR-Y1045/1068/1086F-mCitrine Encoding human EGFR-Y1045/1068/1086F 
with C-terminally fused mCitrine 
EGFR-L834R-mCitrine Encoding human EGFR-L834R with C-
terminally fused mCitrine 
ErbB2-mCitrine Encoding human ErbB2 with C-terminally 
fused mCitrine 
ErbB3-mCitrine Encoding human ErbB3 with C-terminally 
fused mCitrine 
pcDNA3.1+      Empty vector 
tagBFP-Rab11a Encoding human Rab11a with N-terminally 
fused tagBFP 
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c-Cbl-mCherry Encoding human c-Cbl with C-terminally 
fused mCherry 
mCherry-PTP1B-D181A  Encoding PTP1B D181A mutant with N-
terminally fused mCherry 
EGFR-QG-mCitrine Encoding human EGFR with linker inserted 
mCitrine between Q958 and G959 
pHR SFFVp PHAkt Cerulean Encoding PH domain of Akt with C-
terminally fused mCerulean 
pSpCas9(BB)-2A-GFP (PX458) Encoding Cas9 from S. pyogenes with 2A-
EGFP 
tagBFP-PTP1B Encoding human PTP1B with N-terminally 
fused tagBFP 
PTP1B-RFP-tKRas Encoding human PTP1B with C-terminally 
fused RFP and tKRas 
EGFR-paGFP Encoding human EGFR with C-terminally 
fused paGFP 
PTB-mCherry Encoding PTB domain from Shc with C-
terminal mCherry 
HA-Ubiquitin      Encoding HA-Ubiquitin 
eGFP-ERK  Encoding Rat ERK2 N-terminally fused to 
eGFP 
3.1.10 Instruments and equipment  
Eppendorf Research® plus pipettes   Eppendorf 
Falcon tubes (15/50 ml)     BD FalconTM 
Eppendorf safe lock tubes (0.5/1.5/2/5 ml)   Eppendorf 
Heatable magnetic stirrer “IKMAG®RCT”   IKA®Labortechnik 
Heating block ”QBD4”      Grant Instruments 
Nanodrop® ND-1000 spectrophotometer   Peqlab Biotechnologie GmbH 
Parafilm®       Pechiney Plastic Packaging 
PFE powder-free latex exam gloves (S)   Kimberly-Clark 
Pipetboy accu       Integra Biosciences 
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Safegrip® nitril gloves (S)      Süd-Laborbedarf GmbH 
Sarstedt serological pipettes (5/10/25 ml)  Sarstedt  
Surgical disposable scalpel (No. 11, No.21)  Braun Melsungen AG 
Thermomixer comfort      Eppendorf 
“Vortex Genie 1” touch mixer     Scientific Industries 
BioRad Power Pac 300     Bio-Rad Laboratories, Inc. 
BioRad Power Pac HC     Bio-Rad Laboratories, Inc. 
Centrifuge 5415R       Eppendorf 
Centrifuge 5810R       Eppendorf 
1.5 mm cassettes for western blots    InvitrogenTM Life Technologies 
1.5 mm 10-well combs      InvitrogenTM Life Technologies 
1.5 mm 15-well combs      InvitrogenTM Life Technologies 
Incubation box for western blots     Li-Cor® Biosciences 
Incubator Shaker Series I26     New Brunswick Scientific 
Odyssey Infrared Imager      Li-Cor® Biosciences 
Immobilon-FL PVDF      Millipore, Merck KGaA 
Sonicator needle (MS 73)      Bandelin Electronic GmbH 
Ultraschall HD 2200      Bandelin Electronic GmbH 
XCell SureLock™ Mini-Cell  
Electrophoresis System     InvitrogenTM Life Technologies 
XCell II™ Blot Module      InvitrogenTM Life Technologies 
Cell scraper        BD FalconTM 
75 mm filter unit       Nalge Nunc International 
Glass Pasteur pipettes (150 mm, 230 mm)  Brand GmbH & Co. KG 
4-well LabTek® chambers No. 1.0   Nalge Nunc International 
8-well LabTek® chambers No. 1.0   Nalge Nunc International 
35-mm MatTek petri dishes No. 1.5    MatTek Corporation 
NUAIRETM Cellgard class II biological safety  Integra Biosciences 
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cabinet 
Tissue culture plate (6 well)     BD FalconTM 
Vacusafe comfort       Integra Biosciences 
AutoFlow NU-4750 Water Jacket CO2 Incubator Integra Biosciences 
96 well dishes      Corning, Merck 
3.1.11 Software 
Adobe Illustrator      Adobe Systems Inc. 
FV10-ASW Fluoview Software    Olympus 
Fiji       Schindelin et al., 2012113. 
Microsoft Office 2011     Microsoft Corporation 
Odyssey® Infrared Imaging System   LI-COR Biosciences GmbH 
Leica LAS-AF     Leica Microsystems 
GraphPad Prism 6      GraphPad Software, Inc. 
Leica Application Suite X    Leica MICROSYSTEMS 
Python      Python Software Foundation 
CellProfiler      Kamentsky et al., 2011114. 
ImageJ64 v1.44      http://rsbweb.nih.gov/ 
NanoDrop ND-3300 2.6.0    Coleman Technology Inc. 
DNASTAR Navigator v2.2.1.1    DNASTAR Inc. 
Quantity One 4.6.9     Bio-Rad Laboratories, Inc. 
Application software Version 2.1 
Multiscan Ascent Software Version 2.6  ThermoElectron Coorperation 
IgorPRo v6.12      WaveMetrics 
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3.2 Molecular Biology 
3.2.1 Polymerase chain reaction (PCR) 
PCR reactions to amplify target DNA sequences using specific primer pairs were 
performed using the Q5® High-Fidelity DNA Polymerase. The following reaction setup 
and thermocycling Conditions were used: 
Component  Volume [µl] 
5X Q5 Reaction Buffer 10 
10 mM dNTPs 1 
FW Primer (10 µM)  2.5 
BW Primer (10 µM) 2.5 
1-10 ng template DNA X 
Q5 High-Fidelity DNA Polymerase 0.5 
H2O 30.75 – X 
Table 1: 50 µl PCR batch for Q5® High-Fidelity DNA Polymerase. The volume X of the template 
naturally depends on its concentration. 
Cycle  Temperature [°C] Time [s] Cycles 
Initial denaturation 98 30 1 
Denaturation 
Annealing 
Elongation 
95 
*50–72 °C 
72 
10 
20 
30 s/kbp 
30 
Final elongation 72 120  
- 8 hold  
Table 2: PCR-protocol for Q5® High-Fidelity DNA Polymerase. *The annealing temperature, 
depends on the used primers. 
3.2.2 Agarose gel electrophoresis 
DNA strands were separated according to their size using agarose gels with 
concentrations in the range of 1.2 – 2.0 % (w/v) as matrix. Gels were prepared with 
TAE buffer supplemented with the DNA binding dye RedSafeTM (50 µl/l). The size of 
the observed strands was determined by comparison with marker fragments of 
known size using the GelDoc XR System. Designated DNA-fragments were cut out of 
the gel and purified using the “ZymocleanTM Gel DNA Recovery Kit” from Zymo 
Research following the manufacturer’s instructions. 
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3.2.3 Restriction digestion 
Restriction digestion was performed using High-Fidelity (HF®) Restriction 
Endonucleases (New England Biolabs). Restriction batches of 50 µl were prepared 
and incubated at 37 °C for 3 h. 
Component  Volume [µl] 
CutSmart™ Buffer 5 
Restriction 
Endonucleases 
1 each 
5µg template DNA X 
H2O 46 – X 
Table 3: 50 µl restriction batch. The volume X of the template naturally depends on its 
concentration. 
3.2.4 Dephosphorylation of 5’-Phosphorylated DNA fragments 
In order to prevent self-ligation resulting in false positive vector background, 
linearized plasmids were treated with 1 µl calf intestinal phosphatase (CIP) for 15 min 
at 37 °C. 
3.2.5 Ligation of DNA Fragments 
Ligation of DNA fragments and plasmids, was performed using the Quick Ligation™ 
Kit (New England Biolabs). The starting ligation conditions required 50 ng vector DNA 
and threefold excess of the insert DNA. The vector/insert ratio was calculated 
according to the following equation: 𝑛𝑔 vector  ∙  𝑘𝐵(insert)𝑘𝐵(vector) ∙ 3 = 𝑛𝑔(insert) 
The calculated amount of vector/insert DNA was supplemented with 10 µl 2x Quick 
Ligation Buffer, 1 µl of Quick T4 DNA Ligase and H2O to a total reaction volume of 20 
µl. The mixture was incubated for 1 h at room temperature and afterwards for 10 min 
at 65 °C to inactivate the ligase 
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3.2.6 Site-Directed Mutagenesis 
Site-specific mutagenesis of double-stranded plasmid DNA was performed using the 
Q5® Site-Directed Mutagenesis Kit according to the manufactures instructions. 
Custom mutagenic primers to create insertions, deletions and substitutions were 
designed using the NEBaseChanger tool (https://nebasechanger.neb.com/). 
3.2.7 Transformation of chemically competent E. coli cells 
For transformation 50 µl of chemical competent XL 10-Gold cells were used. The 
cells were thawed on ice and 1.75 µl of 2.25 M DTT and 5 µl ligation-reaction mix or 
1 µl plasmid for re-transformation were added and left on ice for 30 min. Afterwards 
cells were heat-shocked for 30 - 60 s at 42 °C and immediately placed on ice for 2 
min. 125 µl SOC medium were added and the cells were incubated at 37 °C for 1 h 
while shaking. In case of a ligation mix, the whole cell suspension was plated on LB 
agar plates containing an appropriate antibiotic for selection. For re-transformation 50 
µl cell suspension were used for plating. 
3.2.8 Plasmid preparation 
Single colonies from LB agar plates were transferred into 5 ml LB-medium containing 
the appropriate antibiotic and incubated overnight at 37 °C and 225 rpm. For MIDI 
preps a pre-culture of 5 ml was grown for approximately 6 h and afterwards used to 
inoculate an overnight culture of 200 ml. Plasmids were purified using the Using 
Roti®-Prep Plasmid MINI kit (Carl Roth GmbH) or the High Pure endotoxin-
freeNucleoBond® Xtra Midi EF kit (MACHEREY-NAGEL) according to the 
manufacturers’ instructions. 
3.2.9 Determination of DNA concentration 
The DNA concentration was determined with the Nanodrop® ND-1000 
spectrophotometer from Peqlab by measuring the absorption at 260 nm. The 
concentration was calculated using the approximation that an OD260 of 1 corresponds 
to a double stranded DNA concentration of 50 ng/µl. 
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3.2.10 DNA Sequencing 
DNA sequences were evaluated using the light-speed Sanger sequencing service 
from GATC (Eurofins GATC Biotech GmbH). Therefore 5 µl of purified plasmid DNA 
(80 - 100 ng/µl) or purified PCR fragments (20 – 80 ng/µl) were premixed with 5 ul of 
the respective sequencing primer (5 µM). 
3.3 Protein biochemistry 
3.3.1 Preparation of cell lysates 
Cells were lysed on ice in ready-made Cell Lysis Buffer (9803, Cell Signaling 
Technology) supplemented with Complete Mini EDTA-free protease inhibitor (Roche 
Applied Science) and phosphatase inhibitor cocktail 2 and 3 (P5726 and P0044, 
Sigma Aldrich). Samples were collected in precooled 1.5 ml tubes and cleared by 
centrifugation for 10 min, 13,000 rpm at 4 ˚C and the supernatant was transferred to 
a fresh precooled 1.5 ml tube. 
3.3.2 Immunoprecipitation  
For immunoprecipitation cell lysis was performed in modified RIPA buffer on ice. 
Following lysis, the samples were subjected to sonication for 12 s and then cleared 
by centrifugation for 15 min, 13,000 rpm at 4 ˚C. Equal amounts of protein lysates 
were incubated with an anti-EGFR antibody (AF231 1:200) over night at 4 ˚C 
followed by incubation for 2 h with Protein-G Sepharose beads. Afterwards the beads 
were incubated with 20 ul 1x SDS sample buffer and incubated for 5 min at 95 °C 
and centrifuged at 16100 g for 1 min. The supernatant was loaded on an SDS gel. All 
wash steps of the Protein-G Sepharose beads were performed with modified RIPA. 
3.3.3 BCA assay 
The protein concentration of whole cell lysates was determined using the Micro 
BCA™ Protein Assay Kit. The assay was performed in a 96-well plate, using 4 µl 
whole cell lysate or BSA standard and 80 µl BCA working reagent (25:24:1, Reagent 
A: B: C). The plate was incubated for 30 min at 37 °C. For calibration, a BSA dilution 
series starting with 0.1 µg/ml up to 20 µg/ml (0.1; 0.2; 0.4; 0.5, 1; 2; 5; 10; 20) was 
measured. Protein concentrations of whole cell lysates were then determined by 
mapping their absorbance values at 562 nm with regard to the standard curve. 
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3.3.4 SDS PAGE 
SDS–PAGE was performed using the X-cell II mini electrophoresis apparatus (Life 
Technologies) according to the manufacturer’s instructions. Cell lysates were mixed 
with 5x SDS sample buffer and incubated for 5 min at 95 °C. Prior loading on a SDS 
polyacrylamide gel samples were centrifuged at 16100 g for 1 min. A molecular 
weight standard was used to assess the correct size of the protein of interest. 
Electrophoresis was performed at a constant voltage of 130 V until for approximately 
90 min. According to the size of the protein of interest different SDS polyacrylamide 
gel compositions were chosen. 
3.3.5 Western blotting 
Following size separation by SDS PAGE, proteins were transferred on a PVDF 
membrane via electroblotting using the XCell II™ Blot Module according to the 
manufacturer’s instructions. The transfer was performed at a constant voltage of 40 V 
for 75 min. Afterwards membranes were blocked for 1 h at room temperature using 
Odyssey infrared imaging system blocking buffer (blocking buffer). Membranes were 
then incubated with the respective primary antibodies diluted in blocking buffer in an 
antibody dependent ratio (1:200 - 1:5000) at 4 °C overnight. For detection 
membranes were incubated with species-specific secondary IR-Dye 800 CW and IR-
Dye 680 CW antibodies (LI-COR Biosciences) for 1 h at room temperature and 
subsequently scanned with the Odyssey Infrared Imaging System (LI-COR 
Biosciences). All wash steps following primary or secondary antibody incubation were 
performed with TBS/T. Following background subtraction, integrated intensities of the 
protein bands of interest were obtained in FIJI and used for further calculations. 
3.4 Cell biology 
3.4.1 Cell culture 
COS-7 and MCF7 cells were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10 % fetal bovine serum (FBS), 2 mM L-glutamine (L-
Glu) and 1 % nonessential amino acids (NEAA) at 37 °C and 5 % CO2. Prior growth 
factor stimulation cells were starved for at least 6 h in DMEM supplemented with 0.5 
% FBS, 2 mM L-Glu and 1 % NEAA. 
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3.4.2 Transient Transfection 
COS-7 and MCF7 cells were transiently transfected using the Fugene® 6 
transfection reagent, according to the manufacturer’s instructions and subsequently 
incubated at 37 °C and 5 % CO2 for at least 6 h before starvation. 
3.4.3 RNA interference 
Transfection of Rab11a siRNA was performed using siRNA transfection reagent and 
transfection medium according to the manufacturer’s instructions. Both Rab11a 
siRNA or scrambled non-targeting control siRNA were used at a final concentration of 
50 nM for 72 h before validation of knockdown. EGFR-mCitrine transfection was 
performed 48 h after siRNA transfection as described above (see Transient 
Transfection). 
ErbB2/3/4 and non-targeting control siRNA were used at a final concentration of 100 
nM for 48 h before validation of knockdown. Transfection was performed using 
Dharmafect1 according to the manufacturer’s instructions. 
3.4.4 CRISPR/Cas9 
pSpCas9(BB)-2A-GFP (PX458) was a gift from Feng Zhang (Addgene plasmid 
#481138). The CRISPR guide sequences were designed using the Broad Institute 
sgRNA design website (https://portals.broadinstitute.org/gpp/public/analysis-
tools/sgrna-design):  
• KSR1 exon 14: 5’-GGATGCCTACCGGGTACCGT-3’ 
• KSR2 exon 2: 5’-AATCGTCGATGTGCGCAAGG-3’ 
The sgRNAs were cloned into the BbsI site of the pX458 expression vector as 
described previously by Ran et al.115. MCF7 cells were plated into 6 well dishes and 
transfected with 2 µg of each pX458 construct using Fugene® 6, cells were FACS 
sorted 24 h post-transfection using GFP expression and seeded into 96 well dishes 
by serial dilutions. Single clones were expanded and evaluated for knockout status 
by western blot analysis for KSR1 and KSR2. 
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3.5 Immunohistochemistry 
3.5.1 In-cell western assay 
Cells were seeded on black, transparent bottomed 96-well plates coated with poly-L-
lysine. Following growth factor administration cells were fixed with 4 % Histofix in 
PBS (v/v) for 5 min at 37 °C and permeabilized with 0.1 % Triton X-100 (v/v) for 5 
min at room temperature. Samples were incubated in Odyssey TBS blocking buffer 
(LI-COR Biosciences) for 30 min at room temperature. Primary antibodies were 
incubated overnight at 4 °C and secondary antibodies (IRDyes, LI-COR Biosciences) 
were incubated for 30 min at room temperature. All wash steps were performed with 
TBS (pH 7.4). Intensity measurements were performed using the Odyssey Infrared 
Imaging System (LI-COR Biosciences). Quantification of the mean intensity in each 
well was performed in FIJI using the MicroArray Profile plugin. 
3.5.2 Immunofluorescence 
Cells grown in 4- or 8-well Labteks were rinsed once with PBS (pH 7.4) and fixed 
using 4 % Histofix or paraformaldehyde in PBS (v/v) for 10 min at room temperature. 
Cells were permeabilized with 0.1 % Triton X-100 (v/v) for 5 min. Background 
staining was blocked by incubation with Odyssey Blocking Buffer for 1 h at room 
temperature. Primary antibodies were applied in an antibody dependent ratio (1:200 - 
1:400) for 1 h 30 min at room temperature or at 4 °C overnight. Secondary antibodies 
were diluted 1:200 and incubated for 1 h at room temperature. Primary and 
secondary antibodies were diluted in Odyssey Blocking Buffer. Fixed cells were 
imaged in PBS. All wash steps following fixation, permeabilization, primary or 
secondary antibody incubation were performed with TBS. 
3.6 Microscopy 
3.6.1 Leica SP5 
The Leica TCS SP5 DMI6000 confocal microscope was equipped with an 
environment-controlled chamber maintained at 37˚C and a HCX PL APO 63x/1.4 NA 
oil objective. Fluorescent proteins were excited using, a 405 nm Cube laser 
(1162002/AF, Coherent, Santa Clara, CA) and 514 nm Argon laser line (LGK 7872 
ML05, Lasos, Jena, Germany), a 561 nm DPSS laser (YLK 6120 T02, Lasos, Jena, 
Germany. Detection of fluorescence emission was restricted with an Acousto-Optical 
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Beam Splitter (AOBS) as follows - BFP (415–458 nm), mCitrine (524–551 nm), 
mCherry (571–623 nm. The pinhole was set to 250 µm and 16-bit images of 512x512 
pixels were acquired. 
3.6.2 Leica SP8 
The Leica TCS SP8 confocal microscope was equipped with an environment-
controlled chamber (LIFE IMAGING SERVICES, Switzerland) maintained at 37 ˚C 
and a HC PL APO CS2 1.4 NA oil objective (Leica Microsystems). Fluorescent fusion 
proteins with mCitrine, mCherry and Alexa647 labeled secondary antibodies were 
excited with a 470–670 nm white light laser (white light laser Kit WLL2, NKT 
Photonics) at 514 nm, 561 nm and 633 nm, respectively. mTagBFP was excited with 
a 405 nm diode laser and mCerulean with a 458 nm Argon laser line. Detection of 
fluorescence emission was restricted with an Acousto-Optical Beam Splitter (AOBS): 
mCitrine (498-551 nm), mCherry (575-675 nm), mCerulean (468-505 nm), mTagBFP 
(425-448 nm), Alexa647 (643–755 nm). The pinhole was set between 1.5 and 2.5 
airy units and 12-bit images of 512x512 pixels were acquired in sequential mode. 
3.6.3 OlympusFV1000 
The Olympus Fluoview FV1000 confocal microscope was equipped with a 
environment-controlled CO2 incubation chamber at 37 ˚C and a 60x/1.35 NA Oil 
UPLSApo objective. Fluorescent fusion proteins with BFP, mCitrine and mCherry or 
Alexa647-, Alexa555-, Alexa488-labeled secondary antibodies were excited using 
the 405 nm Diode-UV laser (FV5-LD05, Hatagaya), 488 nm Argon-laser (GLG 3135, 
Showa Optronics, Tokyo, Japan), 561 nm DPSS laser (85-YCA-020-230, Melles 
Griot) and 633 nm HeNe laser (05LHP-991, Melles Griot), respectively. Detection of 
fluorescence emission was restricted as follows: mTagBFP (425-478 nm), 
mCitrine/Alexa488 (498-551 nm), mCherry/Alexa555 (575-675 nm), Alexa647 (655- 
755 nm). Scanning was performed in frame-by-frame sequential mode with 2x frame 
averaging. The pinhole was set between 1.5 and 2.5 airy units. 
3.6.4 Cell migration 
MCF7 cells were seeded onto fibronectin-coated (F0895, Sigma) 24-well culture 
dishes containing 2-well silicone culture-inserts to create a cell-free area. After the 
culture-insert was removed, cells were stimulated and imaged immediately. Wide 
field images were acquired using an Olympus IX81 inverted microscope equipped 
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with a MT20 illumination system, a 10x/0.16 NA air objective and an Orca CCD 
camera. Transmission images were acquired every 10 min for 12 h. During each 
experiment up to three fields were imaged for each condition. Segmentation of the 
cell-free area was performed using the MRI Wound Healing plugin in FIJI. The 
average distance (D) between the two edges was calculated using the assumption, 
that the length (L) of the cell-free area (A) is constant, since cells did not migrate into 
the field of view from the sites. Also, the width closes in at twice the speed the cell 
migration, resulting in 𝐷 = !!∗!. The edge migration distance in µm (EMD) was 
calculated by relating the obtained distance for a given time point (Dt=i) to the initial 
distance of the cell-free area (Dt=0): 𝐸𝑀𝐷 = 𝐷!!! − 𝐷!!!. This metric is independent of 
the initial distance and thus enables robust quantitative comparison between different 
wells. 
3.6.5 Single cell migration 
MCF7 cells were seeded at low densities on fibronection-coated (F0895, Sigma) 24-
well dishes and nuclei were stained using SiiR-Hoechst (0.5 nM). Transmission and 
fluorescence images were acquired every 10 min for 24 h using an Olympus IX81 
inverted microscope equipped with a MT20 illumination system, a 10x/0.16 NA air 
objective and an Orca CCD camera. Following stimulation individual cells were 
detected and tracked by their nuclear staining in FIJI using the TrackMate plugin 
(https://imagej.net/TrackMate) to extract migration parameters. A minimum track 
length of 40 frames was applied. 
3.7 Analysis of confocal fluorescence imaging data 
All analysis of fluorescence imaging data required an initial background subtraction 
for all images obtained. A cell segmentor tool was developed in-house in Anaconda 
Python (Python Software Foundation, version 2.7, https://www.python.org/) to obtain 
radial profiles. 
3.7.1 Quantification of the EGFR fraction at the RE 
Binary masks of the RE were generated from thresholded BFP-Rab11a images and 
endosomal EGFR from thresholded EGFR-mCitrine images. The integrated 
fluorescence intensity of EGFR-mCitrine was determined from the corresponding 
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endosomal masks. The fraction of endosomal EGFR at the RE was determined by 
dividing EGFR intensities at the RE by total intensities of endosomal EGFR. 
3.7.2 Quantification of the spatial distribution of pY845 
Plasma membrane EGFR-mCitrine and pY845 intensities were quantified as mean 
fluorescence intensities in a 5-pixel ring of the cell periphery. Mean fluorescence 
intensities at the RE were obtained by using binary masks of the RE, generated from 
thresholded BFP-Rab11a images. The difference in the relative phosphorylation level 
(pY845/EGFR-mCitrine) at the PM and RE ((pY845/EGFR)PM - (pY845/EGFR)RE) 
was plotted as a function of the overall EGFR phosphorylation level in individual 
cells. 
3.7.3 Quantification of PH-Akt translocation 
To quantify the plasma membrane recruitment of PH-Akt-mCerulean cells were 
divided into 6 equally spaced radial bins emanating from the nuclear membrane and 
the normalized ratio of the mean intensities between the most inner (cytosol) and 
outer (plasma membrane) segments was measured for individual cells. 
3.7.4 Quantification of ErbB-mCitrine internalization 
To quantify the PM loss of EGFR-, ErbB2- and ErbB3-mCitrine cells were divided into 
11 equally spaced radial bins emanating from the center off mass and the normalized 
ratio of the outer (plasma membrane) segment over the total intensity was measured 
for individual cells. 
3.7.5 Quantification of pRb and CyclinD1 expression 
Mean fluorescence intensities of nuclear pRb and CyclinD1 obtained were obtained 
following segmentation of Hoechst stained nuclei using CellProfiler. 
3.7.6 Quantification of EGFR phosphorylation 
Masks for single cells were generated and mean fluorescence intensities for EGFR-
mCitrine and phospho-specific antibodies were measured in FIJI. The obtained 
values were used to calculate the relative EGFR phosphorylation level (pY/EGFR) for 
individual cells.  
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4 Results 
4.1 Spatial regulation of EGFR activity by vesicular trafficking 
Autocatalytic amplification of ligand-induced EGFR activation ensures robust receptor 
activation to extracellular signals, but on the other hand creates the potential to 
amplify spontaneous phosphorylation events in the absence of growth factors. Since 
the propagation of EGFR activity depends on its the expression level, regulation of 
EGFR plasma membrane abundance and phosphorylation form important 
parameters to suppress spontaneous EGFR activity41,45. Endocytosis of ligand-
activated EGFR has been shown to promote its interaction with spatially distributed 
protein tyrosine phosphatases, however the role of vesicular trafficking in the 
regulation of autonomous receptor activity has not been addressed yet78. In the first 
part of this thesis we examined the role of EGFR vesicular dynamics in the regulation 
of autonomous receptor activity. 
4.1.1 The dependence of spontaneous EGFR phosphorylation on its 
expression level 
To study the dependency of EGFR activity on its plasma membrane density, the 
relative phosphorylation of three tyrosine residues with different regulatory functions 
(autocatalysis, Y845; trafficking, Y1045; and signaling, Y1068) was quantified as a 
function of EGFR expression level in single cells (Fig.7A). Cell-by-cell variation in 
receptor expression following transient transfection of COS-7 cells with EGFR-
mCitrine was exploited to obtain various levels of receptor expression. EGFR 
expression was determined relative to the expression of endogenous EGFR within a 
separate experiment using the abscissa-intercept of a linear fit to an EGFR-mCitrine 
intensity versus anti-EGFR antibody intensity plot (see Baumdick et al. 2015116). The 
expression of EGFR-mCitrine was comparable to the expression level of endogenous 
receptors and varied by a factor of 6 (from ~ 0.5 – 3)116. Single cell 
immunofluorescence analysis revealed that the fraction of phosphorylated receptors 
in unstimulated cells increased for each of the individual residues as function of 
EGFR-mCitrine expression (Fig.7B). The relative phosphorylation between the 
different tyrosine residues showed a higher increase for Y845 (~ sixfold increase) 
and Y1068 (~ eightfold increase) compared to the c-Cbl docking site Y1045 (~ 
twofold increase). In order to quantitatively compare the levels of autonomous 
 44 
phosphorylation between the three residues, the ratio of relative phosphorylation 
(pY/EGFR) before and after stimulation with EGF was calculated (pre/2’EGF). This 
’ratio of fractions’ (pre/EGF) gives a comparable measure, despite potential 
differences in the inherent immunoreactivity of the employed antibodies. This 
analysis showed that the Y1045 site was significantly less phosphorylated as 
compared to tyrosine Y845 and Y1068 (Fig.7C). 
 
Figure 7: Expression level dependency of EGFR phosphorylation. (A) Immunofluorescence 
images of COS-7 cells ectopically expressing EGFR-mCitrine (first column) stained with specific 
pYN-antibodies (second column) and corresponding green/magenta overlay (third column) before 
or after 2 min stimulation with 100 ng/ml EGF. Scale bars = 10 µm. (B) Relative phosphorylation 
(pYN-antibody/EGFR-mCitrine) of the three tyrosine residues (Y845, Y1045, or Y1068) versus 
EGFR-mCitrine expression displayed as n-fold ectopic EGFR expression (see Baumdick et al. 
2015 for details116). Data points (black: pre-; red: 2 min post-stimulation with EGF) represent 
single cells (87 - 145 cells/condition) and thick lines show mean values of binned data ± s.e.m.. 
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(C) Ratio of relative phosphorylation (pY/EGFR) of Y845, Y1045 and Y1068 before (pre) and after 
2 min stimulation with EGF (means ± s.e.m.). (Data obtained together with Dr. G.Xouri, Dr. 
M.Baumdick and Dr. M.Schmick). 
To further assess autonomous EGFR phosphorylation among these distinct 
phosphosites, we performed quantitative Western blot analysis. COS-7 cells were 
transfected with different amounts of EGFR-mCitrine (0.5 µg, 1.5 µg, 3 µg, Fig.8A). 
The level of EGFR expression was determined relative to the maximally applied 
amount of cDNA (3 µg) and the ratio of relative phosphorylation (pre/EGF) before 
and after EGF stimulation was calculated to compare the level of autonomous 
phosphorylation among the three sites (Fig.8B). Similar to the immunofluorescence 
analysis, Y845 and Y1068 phosphorylation were more sensitive to increases in 
EGFR expression than Y0145, indicating higher levels of autonomous 
phosphorylation (Fig.8C). 
 
Figure 8: Expression level dependency of EGFR phosphorylation. (A) Cell lysates of COS-7 
ectopically expressing increasing amounts of EGFR-mCitrine cDNA were collected before or 5 
min post-stimulation with 100 ng/ml EGF. Lysates were immunoblotted for either anti-pY845 (left), 
anti-pY1045 (middle) or anti-pY1068 (right) and anti-tubulin, anti-GFP (EGFR-mCitrine). (B) Ratio 
of the relative phosphorylation (pY/EGFR) of Y845 (n = 5 blots), Y1045 (n = 3), or Y1068 (n = 3) 
before (pre) and after 5 min stimulation with EGF (5’ EGF) from data shown in (A). EGFR-
expression levels are displayed as fraction of EGFR over the respective tubulin band in each lane 
relative to 3 µg cDNA (means ± s.e.m.). (C) Ratio of the relative phosphorylation (pY/EGFR) of 
Y845, Y1045, or Y1068 before (pre) and after 5 min stimulation with EGF (5’ EGF). Data 
correspond to the highest levels of expressed EGFR-mCitrine (3 µg cDNA, means ± s.e.m.). 
Statistical significance in (B) and (C) was determined using an ordinary one-way ANOVA followed 
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by Tukey’s multiple comparison test. (Data were acquired and analyzed together with Dr. 
M.Baumdick). 
The overall level of EGFR phosphorylation results from a continuous and rapid cycle 
of phosphorylation and de-phosphorylation events. In order to distinguish the 
contributions of EGFR kinase activity from the counterbalancing PTP activity in 
generating the autonomous phosphorylation profile, the thiol reactive compound 
pervanadate was employed to globally inhibit PTP activity54. By this means, the 
obtained phosphorylation profile reflects only the catalytic efficiency of EGFR kinase 
for the three tyrosine residues and negates the potential influence of different 
dephosphorylation rates for each residue. Relative phosphorylation levels (pY/EGFR) 
were determined by Western blot analysis of COS-7 cells expressing EGFR-mCitrine 
upon treatment with EGF or PV (Fig.9A). Phosphorylation of Y845 was 
approximately 2.5 times higher upon PV treatment as compared to EGF stimulation, 
while Y1045 and Y1068 displayed similar phosphorylation levels upon either 
treatment (Fig.9B). Comparison of the ratio between autonomous and PV-induced 
phosphorylation allowed an estimation of the relative PTP activity in suppressing 
phosphorylation of the three tyrosine residues. The highest increase was observed 
for Y845 (~ twelve-fold increase), as compared to Y1045 (~ five-fold increase) and 
Y1068 (~ six-fold increase) (Fig.9C). Together these findings show that the 
autocatalytic phosphorylation site Y845 requires higher levels of PTP activity to 
suppress its autonomous phosphorylation as compared to the other two residues. 
The similar PTP activity acting on Y1045 and Y1068 further implies that differences in 
the catalytic efficiency of the EGFR kinase towards specific phospho-sites account 
for the differences observed in their autonomous phosphorylation. 
 
Figure 9: EGFR phosphorylation induced by PV-mediated PTP inhibition and EGF 
stimulation. (A) Lysates of COS-7 ectopically expressing EGFR-mCitrine were collected before 
or 5 min post-stimulation with 100 ng/ml EGF or 10 mM pervanadate (PV). Lysates were 
immunoblotted for either anti-pY845 (left), anti-pY1045 (middle) or anti-pY1068 (right), anti-tubulin 
and anti-GFP (EGFR-mCitrine). (B) Ratio of the relative phosphorylation (pY/EGFR) of Y845 (n = 
3), Y1045 (n = 3), or Y1068 (n = 3) after 5 min treatment with pervanadate (5’ PV) or stimulation 
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with EGF (5’ EGF). (C) Ratio of the relative phosphorylation (pY/EGFR) of Y845, Y1045 or Y1068 
before (pre) and after 5 min treatment with pervanadate (5’ PV). Means ± s.e.m. in (B) and (C). 
Statistical significance in (B) and (C) was determined using an ordinary one-way ANOVA followed 
by Tukey’s multiple comparison test. (Data were acquired and analyzed together with Dr. 
M.Baumdick). 
In order to examine whether autonomously activated EGFR promotes the activation 
of downstream signaling molecules, the phosphorylation of Erk and Akt was 
examined by Western blot analysis (Fig.10A). Interestingly, increasing levels of 
EGFR-mCitrine expression promoted the phosphorylation of Akt, while the 
phosphorylation of Erk was not affected (Fig.10B, C). Similar results were obtained 
upon ectopic expression of an EGFR mutant often found in lung cancer (EGFR-
L834R-mCitrine), which showed elevated phosphorylation levels in the absence of 
ligand, but not upon stimulation with EGF as compared to wild type EGFR (EGFR-
mCitrine)34 (Fig.10D, E). The expression of EGFR-L834R-mCitrine resulted in a 
significant increase of Akt phosphorylation, while the phosphorylation of Erk was not 
significantly affected (Fig.10E). In addition to dimer formation, ligand-induced self-
association of EGFR has also been reported to generate higher-order multimers, 
whose function is poorly understood39,40. We therefore examined whether the distinct 
phosphorylation pattern and signaling behavior of autonomously activated receptors 
and ligand-activated receptors correlates with differences in the self-association state 
of the receptor. Therefore fluorescence anisotropy microscopy measurements were 
performed to detect EGFR self-association via homo-FRET117,118. To this end an 
EGFR construct with mCitrine inserted via a linker between amino acids Q958 and 
G959 (EGFR-QG-mCitrine) was employed, which exhibited a similar phosphorylation 
response as EGFR-mCitrine (see Baumdick et al. 2015116). In the absence of ligand, 
EGFR-QG-mCitrine displayed similar anisotropy values independent of its expression 
level, implying a low self-association state of autonomously activated receptors even 
at high expression levels (Fig.10F). Consistent with this finding, increasing EGFR 
phosphorylation by PV treatment did not induce a change in anisotropy compared to 
unstimulated cells (Fig.10G). In contrast, EGF stimulation resulted in a decrease in 
anisotropy values, demonstrating that ligand binding promotes an increase in 
receptor self-association (Fig.10F). Collectively, these findings suggest that 
autonomously activated and ligand-activated receptors represent different signaling 
entities with distinct states of self-association. 
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Figure 10: Autonomously and ligand-activated receptors represent different signaling 
entities. (A) Lysates of COS-7 ectopically expressing increasing amounts of EGFR-mCitrine 
cDNA were collected before or 5 min post-stimulation with 100 ng/ml EGF. Lysates were 
immunoblotted for anti-pAkt (S473), anti-Akt, anti-pErk, anti-Erk and anti-tubulin. (B) Ratio of the 
relative phosphorylation (pAkt/Akt) of Akt S473 before (pre) and after 5 min stimulation with EGF 
(5’ EGF). EGFR-expression levels are displayed as fraction of EGFR over tubulin band in each 
lane relative to 3 µg cDNA. (n = 3, means ± s.e.m.). (C) Ratio of the relative phosphorylation 
(pErk/Erk) of Erk before (pre) and after 5 min stimulation with EGF (5’ EGF). EGFR-expression 
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levels are displayed as fraction of EGFR over the respective tubulin band in each lane relative to 
3 µg cDNA (n = 3, means ± s.e.m.). Statistical significance in (B) and (C) was determined using 
an ordinary one-way ANOVA followed by Tukey’s multiple comparison test. (D) Lysates of COS-7 
ectopically expressing EGFR-mCitrine or EGFR-L834R-mCitrine cDNA were collected before or 5 
min post-stimulation with 100 ng/ml EGF. Lysates were immunoblotted for anti-GFP (EGFR-
mCitrine), anti-pY1068, anti-pAkt (S473), anti-Akt, anti-pErk, anti-Erk and anti-tubulin. (E) 
Quantification of the relative phosphorylation of EGFR (left), Akt (middle) and Erk (right) (n = 4, 
means ± s.e.m.). Statistical significance was determined using a one sample t test. (F) and (G) 
Left panel: COS-7 cells ectopically expression EGFR-QG-mCitrine and PTB-mCherry to assess 
EGFR phosphorylation and corresponding mCitrine anisotropy before and 5 min post-stimulation 
with 100 ng/ml EGF or 10 mM pervanadate (PV)22,55. Scale bars = 10 µm. Right panel: Anisotropy 
of EGFR-QG-mCitrine versus binned mean fluorescence intensities of EGFR (F of EGFR) before 
and after EGF or PV stimulation (means ± s.e.m.). (Data in (F) and (G) were acquired together 
with Dr. G.Xouri and Dr. M.Baumdick, see Baumdick et al. 2015116). 
4.1.2 EGFR continuously recycles through the pericentriolar recycling 
endosome 
The balance between receptor internalization and recycling determines the density of 
EGFR at the plasma membrane. To assess whether, in the absence of ligand, EGFR 
is maintained at the plasma membrane via vesicular recycling, it was investigated 
whether EGFR partitions in the Rab11-positive pericentriolar recycling endosome 
(RE)119. Both immunofluorescent staining of endogenous Rab11 and EGFR and 
ectopic expression of EGFR-mCitrine and BFP-Rab11a in unstimulated COS-7 cells 
showed co-localization within the perinuclear area (Fig.11A). Ectopic expression of 
BFP-Rab11a resulted in enhanced biogenesis of the RE and thereby shifted the 
distribution of EGFR towards this compartment (Fig.11B). Blocking protein synthesis 
did not affect the localization of either EGFR-mCitrine or BFP-Rab11a, demonstrating 
that co-localization did not originate from newly synthesized EGFR transiting through 
the Golgi via the secretory pathway (Fig.11C). 
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Figure 11: Co-localization of EGFR and Rab11. (A) Upper row: Immunofluorescence images of 
COS-7 cells stained for endogenous EGFR (first column) and Rab11a (second column) with 
corresponding green/magenta overlay (third column). Lower row: Fluorescence images of COS-7 
cells ectopically expressing EGFR-mCitrine and BFP-Rab11a with corresponding green/magenta 
overlay (third column). (B) Quantification of co-localization between EGFR and Rab11 (n = 12-15 
cells/condition) by Pearson’s correlation coefficient (means ± s.e.m.). (Data for ectopic expression 
kindly provided by Dr. G.Xouri). (C) Fluorescence images of two individual COS-7 cells co-
expressing of EGFR-mCitrine, BFP-Rab11a and corresponding green/magenta overlay after 
treatment with cyclohexamide (10 µg/ml) for approximately 20 h. All scale bars = 10 µm. 
In order to assess the kinetics of EGFR recycling, fluorescence loss after 
photoactivation (FLAP) and fluorescence recovery after photobleaching (FRAP) 
measurements were performed (Fig.12A, C). FLAP of EGFR fused to 
photoactivatable GFP (EGFR-paGFP) on Rab11 positive endosomes demonstrated 
that EGFR is exported from the RE (t = 273 ± 15 s) and is concurrently transported to 
the plasma membrane (t = 167 ± 33 s, Fig.12B). The differences in tau can be 
explained due to the differences in the surface area of the PM with respect to the RE, 
which determines the rate PM-association and the RE-dissociation. Fitting the FLAP 
data based on a two-compartment model estimated a residence time of ~7.6 min of 
EGFR at the RE (see Baumdick et al. 2015116). FRAP measurements further 
confirmed that EGFR enters the RE (t = 540 ± 47 s, Fig.12C). Together these 
findings confirm that continuous vesicular recycling of EGFR maintains a steady state 
spatial distribution of the receptors residing at the plasma membrane. In a set of 
complementary experiments, it was further shown that EGFR traffics from the PM to 
the RE through Rab5-positive endosomes. EGF stimulation redirects vesicular 
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trafficking from Rab5-positive endosomes to LAMP1-positive endosomes (see 
Baumdick et al. 2015116). 
 
Figure 12: Continuous recycling of EGFR through the RE. (A) Fluorescence redistribution of 
EGFR-paGFP upon photoactivation on the RE in COS-7 cells. First row EGFR-paGFP before 
(black rectangle) and after photoactivation for the indicated times in seconds, second row: 
corresponding fluorescence images of EGFR-mCherry, third row: fluorescence image of BFP-
Rab11a. (B) Loss of EGFR-paGFP/EGFR-mCherry fluorescence at the RE (left) and concomitant 
gain of at the PM (right). Normalized average traces (mean ± s.e.m., n = 6 cells) were fitted to an 
exponential function (red) to retrieve time constants (t). (C) Fluorescence recovery after 
photobleaching of EGFR-mCitrine in COS-7 cells co-expressing BFP-Rab11a before and after 
photobleaching (black rectangle) for the indicated times in seconds. (D) Normalized mean 
fluorescence intensity of the bleached area (red line: mean values, grey lines: individual recovery 
curves, n = 16 cells). All scale bars = 10 µm. (Data kindly provided by Dr. G.Xouri, Dr. 
M.Baumdick and Dr. M.Schmick). 
4.1.3 Vesicular recycling suppresses autonomous EGFR activation 
Next, to examine the contribution of vesicular recycling to the regulation of 
autonomous EGFR phosphorylation, the biogenesis of the RE was decreased by 
siRNA mediated knockdown of Rab11 or enlarged upon ectopic expression of BFP-
Rab11a (Fig.13A, E, G) and EGFR phosphorylation was measured via 
immunofluorescence in COS-7 cells ectopically expressing EGFR-mCitrine (Fig.13C, 
G). Knockdown of Rab11 with two different pools of siRNAs resulted in a significant 
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increase in phosphorylation of the autocatalytic site Y845 (~ threefold) and to a lesser 
extend of Y1045 (~ 1.5-fold), without affecting the expression levels of EGFR-
mCitrine (Fig.13B, D, F). In contrast, Rab11 knockdown did not affect the 
phosphorylation of Y1068. In agreement with these findings, ectopic expression of 
BFP-Rab11a lowered the phosphorylation levels of Y845 and Y1045, while the 
phosphorylation of Y1068 was not affected (Fig.13H). Comparison of the 
phosphorylation levels of Y845 at the PM and RE revealed higher phosphorylation at 
the PM compared to the RE (Fig.13I). Together these findings imply that vesicular 
recycling EGFR through perinuclear recycling endosomes reduces autonomous 
receptor activation. 
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Figure 13: Suppression of autonomous EGFR activation by vesicular recycling. (A) Left 
panel: Lysates of COS-7 cells 72 h post-transfection with non-targeting siRNA (Ctrl) or Rab11a 
siRNA (siRab11a) were immunoblotted and probed for anti-Rab11a and anti-GAPDH. Right 
panel: Normalized ratio of Rab11a to GAPDH (means ± s.e.m., n = 5). (B) EGFR-mCitrine 
expression upon Rab11a knockdown. Lysates of COS-7 cells EGFR-mCitrine after transfection 
with non-targeting siRNA (Ctrl) or Rab11a siRNA (siRab11a) were immunoblotted and probed for 
EGFR-mCitrine pY845
BFP-Rab11a Ratio pY845/EGFR
0
1 Δ 
(p
Y
84
5 
/ E
G
FR
)
1.20.80.4
pY845 / EGFR
0.5
0.0
B. 
p<0.0001
Rab11a
GAPDH
Ctrl Rab11asiRNA
1.0
0.8
0.6
0.4
0.2
0.0
ctrl
Rab11a
R
ab
11
a 
/ G
A
P
D
H
 (a
.u
.)
A. 
Ctrl Rab11asiRNA
Rab11a
GAPDH
EGFR-mCitrine
EGFR-mCitrine α-pY1068EGFR-mCitrine α-pY1045
ct
rl 
si
RN
A
Ra
b1
1a
 s
iR
NA
EGFR-mCitrine α-pY845
C. 
ctrl siRNA
Rab11a siRNA
p=0.026
p=0.047
p=0.56
Y845 Y1045 Y1068
4
3
2
1
0
pY
 / 
EG
FR
GAPDH
Rab11a/b
siRNA
Rab
11aCtrl
Rab
11a/b
ctrl siRNA
Rab11a/b siRNA
p<0.0001
p<0.0001
p=0.68
Y845 Y1045 Y1068
3
2
1
0
pY
 / 
EG
FR
D. E. F. 
G. 
EGFR-mCitrine pY845 BFP-Rab11a EGFR-mCitrine pY1045 BFP-Rab11a EGFR-mCitrine pY1068 BFP-Rab11a
+ pcDNA3.1
+ Rab11a
p=0.061 p=0.11
p=0.99
Y845 Y1045 Y1068
1.5
1.0
0.5
0.0
pY
 / 
EG
FR
H. I. 
 54 
anti-Rab11a, anti-GAPDH and anti-GFP (EGFR-mCitrine). (C) COS-7 cells expressing EGFR-
mCitrine were immunostained with specific pYN-antibodies to detect phosphorylation of Y845, 
Y1045, and Y1068 upon transfection with non-targeting siRNA (Ctrl, upper columns) or upon 
siRNA-mediated Rab11a knockdown (Rab11a, lower columns). (D) and (F) Relative 
phosphorylation (pY/EGFR) of EGFR-mCitrine on Y845, Y1045, and Y1068 upon siRNA-
mediated Rab11a (D) or Rab11a/b (F) knockdown normalized to pY/EGFR for cells transfected 
with non-targeting siRNA (means ± s.e.m., n=69-147 cells/condition). (E) Lysates of COS-7 cells 
72 h post-transfection with non-targeting siRNA (Ctrl), Rab11a siRNA (siRab11a) or Rab11a/b 
were immunoblotted and probed for anti-Rab11a/b and anti-GAPDH. (G) COS-7 cells expressing 
EGFR-mCitrine were immunostained with specific pYN-antibodies to detect phosphorylation of 
Y845, Y1045, and Y1068 in the presence of empty pcDNA 3.1 or BFP-Rab11a. (H) Relative 
phosphorylation (pY/EGFR) of EGFR-mCitrine on Y845, Y1045, and Y1068 upon ectopic 
expression of BFP-Rab11a normalized to pY/EGFR for cells transfected with empty pcDNA 3.1 
(means ± s.e.m., n = 34-138 cells/condition). Data were acquired together with Dr. M.Baumdick. 
(I) Spatial distribution of autonomously phosphorylated Y845 in COS-7 cells. Left panel: 
Fluorescence images of EGFR-mCitrine, immunostaining of pY845, BFP-Rab11a, and a ratio 
image of pY845/EGFR-mCitrine. Right panel: Difference in Y845 auto-phosphorylation between 
the PM and RE (D pY845 over EGFR) as a function of overall EGFR phosphorylation level in 
individual cells (pY845/EGFR). All scale bars = 10 µm. Statistical significance was determined 
using a one sample t test. Data in (D) and (F) kindly provided by Dr. M.Baumdick. 
4.1.4 PTP1B dephosphorylates autonomously activated EGFR in the 
perinuclear area 
Previous studies showed that upon ligand-induced internalization, EGFR is 
dephosphorylated within perinuclear area by the ER-associated phosphatase 
PTP1B59,77,78. To assess whether PTP1B is also implicated in the regulation of 
autonomously activated EGFR, phosphorylation of EGFR-mCitrine in COS-7 cells co-
expressing BFP-PTP1B was assessed via immunofluorescence and Western blotting 
(Fig.14A, C). The overall phosphorylation on the three tyrosine residues (Y845, 
Y1045, Y1068) was significantly lowered upon ectopic expression of BFP-PTP1B as 
compared to control cells (Fig.14B, D). In order to spatially resolve where 
autonomously activated EGFR is dephosphorylated by PTP1B, the interaction 
between EGFR-mCitrine and a substrate trapping mutant of PTP1B (mCherry-
PTP1B-D181A) was examined by FLIM-FRET78. The catalytically impaired substrate 
trapping mutant retains its ability to bind substrate proteins and therefore can be 
employed to identify substrate complexes within the cell120. The spatially distributed 
interacting fraction (α) of EGFR-mCitrine with mCherry-PTP1B-D1881A obtained by 
global analysis, revealed an interaction between both proteins in the perinuclear 
area121 (Fig.14E). The mean spatial coincidence of this interaction and BFP-Rab11a 
(63 ± 29 %; n = 20 cells) implied that receptor dephosphorylation mainly occurs 
within the perinuclear area in close proximity to the RE. Ectopic expression of BFP-
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Rab11a shifted the distribution of EGFR towards this compartment, leading to an 
elevated interacting fraction between mCherry-PTP1B-D1881A and EGFR-mCitrine. 
Targeting PTP1B to the plasma membrane using the C-terminal membrane 
anchoring residues of KRas (PTP1B-RFP-tKRas) rendered EGFR unresponsive to 
ligand stimulation (Fig.14F, H), demonstrating that the spatial segregation of 
catalytically superior PTPs from EGFR is a prerequisite to permit growth factor 
induced receptor activation56–58. Collectively these findings show that vesicular 
recycling of EGFR through perinuclear areas promotes its interaction with the ER-
associated PTP1B, thereby reducing autonomous activation of the receptor in the 
absence of ligand, while maintaining responsiveness to EGF stimulation. 
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Figure 14: PTP1B dephosphorylates autonomously activated EGFR in the perinuclear area. 
(A) Lysates of COS-7 cells ectopically expressing EGFR-mCitrine in the presence of empty 
pcDNA 3.1 or BFP-PTP1B were immunoblotted and probed for either anti-pY845 (left), anti-
pY1045 (middle) or anti-pY1068 (right), anti-tubulin, anti-GFP (EGFR-mCitrine) and anti-tRFP 
(BFP-PTP1B). (B) Relative phosphorylation (pY/EGFR) of EGFR-mCitrine on Y845, Y1045, and 
Y1068 upon ectopic expression of BFP-PTP1B normalized to pY/EGFR for cells transfected with 
empty pcDNA 3.1 (means ± s.e.m., n = 4 - 5). (C) COS-7 cells expressing EGFR-mCitrine were 
immunostained with specific pYN-antibodies to detect phosphorylation of Y845, Y1045, and 
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Y1068 in the presence of empty pcDNA 3.1 or BFP-PTP1B. (D) Relative phosphorylation 
(pY/EGFR) of EGFR-mCitrine on Y845, Y1045, and Y1068 upon ectopic expression of BFP-
PTP1B normalized to pY/EGFR for cells transfected with empty pcDNA 3.1 (means ± s.e.m., n = 
51 - 61 cells/condition). Data acquired together with Dr. Martin Baumdick. (E) Interacting fraction 
(α) of EGFR-mCitrine with mCherry-PTP1B D/A in COS-7 cells detected by FLIM-FRET, with 
(upper row) or without (lower row) ectopic expression of BFP-Rab11a. Graph shows average α in 
regions of high EGFR-mCitrine intensity as function of the EGFR mean fluorescence (F of EGFR) 
with (blue, n = 28 cells) or without ectopic expression of BFP- Rab11a (black, n = 20 cells). Lower 
row: Percentage of EGFR/PTP1B D/A interactions in the vicinity of the RE was retrieved from the 
overlap (III) between areas with high α values (I) and areas with high intensity of BFP-Rab11a 
fluorescence (II). Data in kindly provided by Dr. Martin Baumdick and Angel Stanoev (see 
Baumdick et al. 2015116). (F) COS-7 cells expressing EGFR-mCitrine were immunostained to 
detect phosphorylation of Y1068 and upon co-expressiong of PTP1B-tk before (upper rows) and 
after 5 min stimulation with 100 ng/ml EGF (lower rows). (H) Quantification of the relative EGFR-
mCitrine phosphorylation (pY1068/EGFR-mCitrine) before (pre) and after stimulation with 100 
ng/ml EGF in COS-7 cells ectopically expressing PTP1B-RFP-tkRas and control cells (means ± 
s.d., n = 22 - 40 cells/condition). Statistical significance was determined using an ordinary one-
way ANOVA followed by Tukeys multiple comparison test (****, p > 0.0001). All scale bars = 10 
µm. Statistical significance in (B) and (D) was determined using a one sample t test. 
4.1.5 EGF triggers a ubiquitin-mediated switch in vesicular trafficking of EGFR 
Constitutive vesicular recycling in the absence of ligand reduces autonomous 
receptor activation, while maintaining a steady state population of EGFR at the 
plasma membrane. In contrast, EGF stimulation results in enhanced receptor 
internalization, trafficking towards the perinuclear area and subsequent lysosomal 
degradation (Fig.15A). EGF stimulation triggers ubiquitination of the receptor by the 
E3-ligase c-Cbl, resulting in lysosomal degradation of the receptor71. In order to 
assess whether ubiquitination functions as the decisive signal to switch vesicular 
trafficking of ligand-activated EGFR towards lysosomal degradation, the amount of 
receptor ubiquitination was assessed upon EGF and PV treatment (Fig.15B). EGF 
stimulation induced higher levels of receptor ubiquitination and degradation as 
compared to autonomously activated EGFR upon PV treatment (Fig.15C). In line 
with these observations autonomously activated receptors did not recruit c-Cbl and 
continued to traffic via the Rab11-positive RE (Fig.15D, E). In contrast, EGF 
stimulation recruited c-Cbl to EGFR positive endosomes and reduced the fraction of 
EGFR at the RE. Together these findings imply that c-Cbl mediated ubiquitination 
redirects EGFR from continuous vesicular recycling towards lysosomal degradation. 
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Figure 15: EGF triggers a ubiquitin-mediated switch in vesicular trafficking of EGFR (A) 
Immunofluorescence images of COS-7 cells stained for endogenous EGFR (left panel) and 
quantification of mean EGFR fluorescence intensities (right panel) following stimulation with 100 
ng/ml EGF for the indicated time points (means ± s.d., n = 14 - 32 cells/condition). Statistical 
significance in was determined using an ordinary one-way ANOVA followed by Sidak’s post-hoc 
test. (B) COS-7 cells expressing EGFR-mCitrine, HA-c-Cbl-mCherry and HA-Ubiquitin were 
treated with 100 ng/ml EGF or 0.33 mM PV for the indicated times in min. Lysates were 
immunoprecipitated with anti-EGFR (left panel) or blotted for total proteins (right panel). IP was 
probed with anti-HA (HA-ubiquitin) and anti-GFP (EGFR-mCitrine) and total lysates were probed 
with anti-GFP (EGFR-mCitrine), anti-Cbl (c-Cbl-mCherry), anti-tubulin, and anti-pY1045. (C) 
Relative EGFR ubiquitination (Ub/EGFR, upper panel) and EGFR-mCitrine degradation 
(EGFR/Tubulin, lower panel). Means ± s.e.m. (n = 3). (D) Fluorescence images of COS-7 cells 
expressing EGFR-mCitrine, BFP-Rab11a and HA-c-Cbl-mCherry upon stimulation with 100 ng/ml 
EGF (left panel) or 0.33 mM PV (right panel) for the indicated times in min. (E) Fraction of EGFR-
mCitrine fluorescence at the RE upon treatment with 100 ng/ml EGF (n = 12 cells) or 0.33 mM PV 
(n = 14 cells). Statistical significance in was determined using an ordinary one-way ANOVA 
followed by Tukey’s multiple comparison test. All scale bars = 10µm. 
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Mutation of the c-Cbl binding site within the C-tail of EGFR (EGFR-Y1045F-Citrine), 
also impaired c-Cbl recruitment, resulting in constitutive recycling of the receptor 
upon EGF stimulation (Fig.16A). Perturbing the EGFR-c-Cbl interaction via 
mutagenesis of the direct (Y1045) and indirect Grb2-mediated binding sites (Y1068 
and 1086) further resulted in equally sustained receptor phosphorylation as 
compared to the remaining fraction of wild type EGFR, lower levels of c-Cbl 
phosphorylation and ultimately impaired receptor degradation (Fig.16B, C). 
Interestingly, phosphorylation of Y1045 was not is not sufficient for the recruitment of 
c-Cbl as PV and EGF treated cells displayed comparable levels of Y1045 
phosphorylation, indicating the necessity of EGF induced self-association of the 
receptor to promote efficient receptor ubiquitination (Fig.15B). EGF promoted 
receptor ubiquitination thereby functions as a secondary signal, which redirects 
EGFR towards lysosomal degradation to avoid reactivation at the PM, imposing a 
finite response of receptor activity. 
 
Figure 16: Continuous recycling of ubiquitination-deficient EGFR. (A) Left panel: 
Fluorescence images of COS-7 cells expressing EGFR-Y1045F-mCitrine, BFP-Rab11a and HA-
c-Cbl-mCherry upon stimulation with 100 ng/ml EGF (for the indicated times in min. Right panel: 
Fraction of EGFR-Y1045F-mCitrine fluorescence at the RE upon treatment with 100 ng/ml EGF 
(means ± s.e.m., n = 9 cells) for the indicated times in min (Data kindly provided by Dr. M. 
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Baumdick). Scale bar = 10 µm. (B) Lysates of COS-7 cells expressing EGFR-mCitrine or EGFR-
Y1045F-mCitrine or EGFR-Y1045/1068/1086F-mCitrine and HA-c-Cbl-mCherry were collected 
before or after stimulation with 100 ng/ml for the indicated times in min. Lysates were 
immunoblotted and probed with the generic phospho tyrosine antibody PY72, anti-GFP (EGFR-
mCitrine), anti-tubulin and anti-c-Cbl. (C) Quantification of EGFR degradation (EGFR/Tubulin, 
left), relative EGFR phosphorylation (PY72/EGFR) and relative c-Cbl phosphorylation (PY72/Cbl) 
for wild type EGFR and ubiquitination-deficient EGFR mutants (means ± s.e.m. n = 3). Statistical 
significance in (C) was determined using an ordinary one-way ANOVA followed by Tukey’s 
multiple comparison test. 
4.2 Ligand-specific ErbB receptor trafficking determines Erk signaling 
specificity 
The ErbB signaling network mediates fundamental, often opposing cellular 
responses including proliferation, differentiation, migration, survival and/or apoptosis. 
Intriguingly, despite the promiscuous activation of shared signal transducing proteins, 
such as the Ras/Erk cascade, different ErbB ligands can induce distinct cellular 
responses. Vesicular membrane dynamics allow the cell to regulate the spatial 
distribution of cell surface receptors between the plasma membrane and different 
endosomal compartments. In the second part of this thesis we examined how ligand-
specific differences in the spatial organization of active ErbB receptors determines 
Erk signaling dynamics and localization to generate different cellular responses. 
4.2.1 HRG and EGF induce distinct spatial distributions of active ErbB 
receptors 
The human breast cancer cell line MCF7 endogenously expresses all ErbB family 
members (EGFR, ErbB2/3/4), activation of ErbB receptors by EGF or HRG promotes 
transient and sustained activation of Erk, respectively (Fig.17A). Administration of the 
ErbB inhibitor Lapatinib 10 min after HRG treatment resulted in a loss of Erk 
phosphorylation, demonstrating the necessity of prolonged ErbB signaling for 
persistent Erk activation (Fig.17B). EGF is a specific ligand for EGFR, while HRG 
binds to ErbB3 and ErbB4 and further promotes transactivation ErbB2 via receptor 
hetereodimerization52. To elucidate which receptors, mediate the sustained Erk 
response upon HRG stimulation, we performed siRNA knockdown experiments for 
ErbB2, ErbB3 and ErbB4. Knockdown of either ErbB2 or ErbB3 reduced HRG-
induced Erk activation, while ErbB4 knockdown had no effect, implying that ErbB2/3 
heterodimers form the major HRG responsive receptor complex with regard to Erk 
activation (Fig.17C, D). 
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Figure 17: EGF and HRG induce different temporal responses of Erk. (A) Time-dependent 
Erk activation profiles were measured by ICW in MCF7 cells stimulated with 100 ng/ml EGF or 
HRG for the indicated times (means ± s.e.m., n = 3). (B) Erk phosphorylation upon ErbB inhibition 
were measured by ICW in MCF7 cells stimulated with 100 ng/ml HRG for 10 min and 
subsequently treated with DMSO or 2 uM Lapatinib (means ± s.e.m., n = 3). (C) Lysates of MCF7 
cells transfected with non-targeting siRNA (control) or siRNA targeting ErbB receptors were 
collected following stimulation with 100 ng/ml HRG for the indicated times. Lysates were 
immunoblotted and probed for ErbB receptors, anti-pErk, anti-Erk and anti-tubulin. (D) 
Quantification of Erk activation upon ErbB receptor knockdown for ErbB2 (left), ErbB3 (middle), 
ErbB4 (right). 
To address the impact of EGF and HRG on the localization of the respective ErbB 
receptors, immunofluorescence measurements of endogenous receptors and live cell 
confocal imaging of fluorescently tagged receptors were performed (Fig.18.A-C). 
EGF-stimulation resulted in rapid EGFR internalization, while upon HRG stimulation 
ErbB2 and ErbB3 were not internalized and remained at the plasma membrane 
(Fig.18A-C). In agreement with this, HRG-induced activation of ErbB2 and ErbB3 did 
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not promote receptor degradation, while EGFR was rapidly degraded upon EGF 
stimulation (Fig.18D). 
 
Figure 18: ErbB localization and degradation upon EGF and HRG stimulation. (A) 
Representative immunofluorescence images of MCF7 cells stained for endogenous EGFR (top), 
ErbB3 (middle) and ErbB2 (bottom) before and after 30 min with 100 ng/ml EGF or HRG, 
respectively. Nuclei were stained with Hoechst. (B) Fluorescence images of MCF7 cells 
expressing EGFR-mCitrine (top), ErbB2-mCitrine (middle) and ErbB3-mCitrine (bottom) before 
and after with 100 ng/ml EGF or HRG for the indicated times, respectively. (C) Quantification of 
the normalized relative plasma membrane fractions of EGFR-mCitrine upon EGF stimulation and 
ErbB2/3-mCitrine upon HRG stimulation (means ± s.e.m., n = 11 cells/condition). (D) Upper 
panel: Lysates of MCF7 cells following stimulation with 100 ng/ml EGF or HRG for the indicated 
times were immunoblotted and probed for EGFR upon EGF stimulation and ErbB2/3 upon HRG 
stimulation. Anti-tubulin was used as loading control. Lower panel: Quantification of total ErbB 
abundance normalized to unstimulated conditions (means ± s.e.m, n = 3). Statistical significance 
was determined using a one-way ANOVA with Dunnett’s post-hoc test (****, p > 0.0001; ***, p > 
0.001). All scale bars = 10µm. 
The differences in receptor internalization and degradation were further reflected in 
the temporal ErbB activity, as EGF stimulation resulted in transient phosphorylation 
of EGFR and HRG induced sustained activity of ErbB2 and ErbB3 (Fig.19A). To 
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further test whether HRG stimulation also induced sustained downstream ErbB 
signaling from the plasma membrane, we used an PH-Akt based translocation sensor 
for phosphatidylinositol 3,4,5-triphosphate (PtdIns(3,4,5)P3)122. Since 
PtdIns(3,4,5)P3-production is spatially restrained to the plasma membrane this 
sensor can be employed to selectively probe for plasma membrane receptor activity. 
EGF induced a weak, transient recruitment of the sensor to the PM, while HRG 
promoted stronger and more sustained PM recruitment (Fig.19B). The HRG-
promoted translocation of PH-Akt was reversed following treatment with the tyrosine 
kinase inhibitor Erlotinib, indicating that PH-Akt translocation directly reflects PM 
ErbB receptor activity (Fig.19C). Interestingly, the duration of the PH-Akt 
translocation response upon EGF stimulation was markedly shorter (∼10 min, 
Fig.19B) than the respective Erk response (∼30 min, Fig.17A). Previous studies 
showed that endosomal EGFR can continue to activate Erk following 
internalization123. To assess whether EGFR continues to activate Erk from 
endosomal membranes we pulsed cells for 10 min with EGF to allow internalization 
of active receptors and then removed extracellular EGF to prevent further EGFR 
activation at the PM (Fig.19D). EGF-induced Erk activation following pulsed 
stimulation was identical to sustained stimulation, suggesting that EGFR continues to 
activate Erk from endosomal membranes following internalization. On the other hand, 
pulsed stimulation with HRG generated a transient Erk response, indicating the 
necessity of persistent PM receptor activity to sustain Erk activation during HRG 
stimulation (Fig.19D). HRG and EGF thus induce distinct spatiotemporal patterns of 
active ErbB receptors during stimulation, leading to the activation of Erk from different 
subcellular compartments (PM and endosomes, respectively). Finite EGFR activation 
due to rapid internalization and lysosomal degradation further limited its capacity to 
efficiently engage Akt activation at the plasma membrane, as compared to HRG 
activated ErbB2/3 (Fig.19E). 
 64 
 
Figure 19: HRG and EGF promote different spatial and temporal localizations of active 
ErbB receptors. (A) Upper panel: Lysates of MCF7 cells following stimulation with 100 ng/ml 
EGF or HRG for the indicated times were immunoblotted and probed for anti-EGFR and anti-
pY1068 upon EGF stimulation and anti-ErbB2/3 and anti-pY1289 (ErbB3) or anti-pY1221/2 
(ErbB2) upon HRG stimulation. Lower panel: Quantification of ErbB phosphorylation normalized 
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to 5 min stimulation (means ± s.e.m., n = 3). Statistical significance was determined using a one-
way ANOVA with Dunnett’s post-hoc test (****, p > 0.0001; ***, p > 0.001; **, p > 0.001). (B) Left: 
Fluorescence images of MCF7 cells expressing PH-Akt-mCerulean before and after stimulation 
with 100 ng/ml EGF (top) or HRG (bottom) for the indicated times. Right: Quantification of 
normalized PH-Akt recruitment (means ± s.e.m., n = 8-10 cells/condition). (C) Left: Fluorescence 
images of MCF7 cells expressing PH-Akt-mCerulean were stimulated with 100 ng/ml HRG and 
after 20 min treated with 10 µM Erlotinib. Right: Quantification of normalized pH-Akt recruitment 
(means ± s.e.m., n = 6 cells). (D) Time-dependent Erk activation profiles were measured by ICW 
in MCF7 cells following sustained stimulation with 100 ng/ml EGF or HRG or a 10 min pulsed 
stimulation and subsequent washout. (means ± s.e.m., n = 3). (E) Time-dependent Akt activation 
profiles were measured by ICW in MCF7 cells following sustained stimulation with 100 ng/ml EGF 
or HRG for the indicated times (means ± s.e.m., n = 4). All scale bars = 10 µm. 
4.2.2 KSR enhances HRG-induced Erk activation at the PM 
Scaffolding proteins play a critical role in the assembly of many multiprotein 
complexes that drive signal transduction and have been shown to promote Erk 
activation from various subcellular localizations (e.g. PM, endosomes, golgi, 
nucleus)124. As such, KSR proteins have been shown to be translocate to the plasma 
membrane and facilitate the activation of Mek and thus Erk from the plasma 
membrane upon growth factor stimulation125. Given that HRG stimulation promotes 
Erk activation specifically from the plasma membrane, we examined whether KSR is 
implicated in the HRG-induced Erk response. We employed CRISPR-Cas9 genome 
editing to knock out both KSR1 and KSR2 proteins and examined two single cell 
derived clones, to account for potential clonal effects (Fig.20A). Knockout of KSR1/2 
attenuated HRG-induced Erk phosphorylation, while EGF-induced Erk 
phosphorylation was not affected (Fig.20B). Different temporal Erk activities can be 
decoded at the level of immediate early genes (IEG) like cFos, which selectively 
respond to sustained Erk signals. Consistent with the reduction of HRG-induced Erk 
activation, knockdown of KSR1/2, specifically reduced cFos accumulation in 
response to HRG, while the smaller EGF-induced cFos accumulation was not 
affected (Fig.20C). The contrasting effects of KSR knockout on the EGF- versus or 
HRG-induced Erk activation and downstream signaling further reflect the differences 
in the spatiotemporal patterns of ErbB activity generated by these ligands. 
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Figure 20: KSR enhances HRG-induced Erk activation at the PM. (A) Cell lysates of wild type 
MCF7 (WT) or MCF7 KSR knockout cells (Clone1/2) were immunoblotted for anti-KSR1, anti-
KSR2 and anti-tubulin. (B) Time-dependent Erk activation profiles were measured by ICW in 
MCF7 wild type or MCF7 KSR knockout cells (Clone1/2) stimulated with 100 ng/ml EGF or HRG 
for the indicated times (means ± s.e.m, n = 4). (C) Left: Cell lysates of wild type MCF7 (WT) or 
MCF7 KSR knockout cells (Clone1/2) following 1 h stimulation with 100 ng/ml EGF or HRG were 
immunoblotted for anti-c-Fos and anti-tubulin. Right: Quantification of cFos expression for wild 
type MCF7 or MCF7 KSR knockout cells (means ± s.e.m, n = 3). Statistical significance was 
determined in using a repeated measures one-way ANOVA with a Dunnett’s post-hoc test (**,p > 
0.01; *, p > 0.05). 
4.2.3 EGF and HRG promote Erk-dependent cell proliferation 
To determine if the differences in the spatial distribution of EGF-activated EGFR and 
HRG-activated ErbB2/3 and the resultant spatial and temporal dynamics of Erk 
activity generate distinct cellular outcomes, we next investigated the effects of EGF 
and HRG stimulation on cell proliferation. Erk signaling plays a pivotal role regulating 
cellular proliferation in response to growth factors via nuclear translocation and 
activation of multiple transcription factors. Phosphorylated retinoblastoma protein 
(pRb) and CyclinD1 were employed as indicators of cell proliferation and assessed 
by immunofluorescence in individual cells (Fig.21A, C). Both ligands induced a 
similar increase in the fraction pRb-positive positive cells and CyclinD1 expression as 
compared to control cells treated with DMEM (Fig.21B, D). We confirmed the role of 
Erk activation on cell proliferation using the noncompetitive Mek inhibitor PD0325901 
(PD03), which efficiently suppressed Erk phosphorylation in MCF7 cells upon EGF 
and HRG stimulation (Fig.21E). Treatment with PD03 significantly reduced the 
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fraction of pRb-positive cells for both EGF and HRG, directly demonstrating the 
requirement of Erk activity for EGF- and HRG-induced cell proliferation (Fig.21F). 
Together these findings show that differences in the spatiotemporal activation of Erk 
(PM/sustained versus endosomes/transient), do not influence its capability to transmit 
growth factor signals to the nucleus to initiate a proliferative cellular response. 
 
Figure 21: EGF and HRG induce Erk-dependent cell proliferation. (A) Immunofluorescence 
images of MCF7 cells stained for phospho-Rb (Ser807/811) following 24 h stimulation with 100 
ng/ml EGF or HRG and control cells treated with DMEM. Nuclei were stained with Hoechst. (B) 
Left: Distribution of pRb fluorescence intensities for all measured cells. A minimum mean 
fluorescence intensity of 70 was used as a threshold to distinguish between pRb-negative and -
positive cells (n = 12643 cells). Right: Quantification of pRb-positive cells (means ± s.e.m., n = 5) 
following 24 h stimulation with 100 ng/ml EGF or HRG and control cells treated with DMEM. (C) 
Immunofluorescence images of MCF7 cells stained for CyclinD1 following 24 h stimulation with 
100 ng/ml EGF or HRG and control cells treated with DMEM. Nuclei were stained with Hoechst. 
(D) Quantification of CyclinD1 expression in MCF7 cells (n = 3075 - 3482 cells/condition) (E) 
Lysates of MCF7 cells following stimulation with 100 ng/ml EGF or HRG for the indicated times 
upon pretreatment with DMSO or PD03 (1 uM, 1h) were immunoblotted and probed with anti-Erk 
and anti-pErk. (F) Quantification of pRb-positive cells (means ± s.e.m., n = 3 - 5) following 24 h 
stimulation with 100 ng/ml EGF or HRG in control cells and cells treated with PD03 (1 uM). 
Control data previously shown in (B). Statistical significance in (B), (D) and (F) was determined 
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using an ordinary one-way ANOVA followed by Tukey’s multiple comparison test (****, p > 
0.0001; ***, p > 0.001; **, p > 0.01). All scale bars = 10 µm. 
4.2.4 HRG stimulation promotes cellular motility 
Erk signaling has also been previously described to play an essential role controlling 
cellular motility126. To assess the contribution of EGF and HRG to cellular motility, 
MCF7 cells were grown to a confluent monolayer in a 2-well culture-insert to create a 
defined cell-free area, while causing minimal cell damage (Fig.22A). Following 
removal of the confinement, cells were uniformly stimulated with EGF or HRG and 
the relative migration distance of the edges was quantified. Stimulation with HRG 
induced in a significant increase in migration, while EGF stimulation had no effect on 
cellular motility relative to non-treated control cells (Fig.22B). Treatment with the Mek 
inhibitor PD0325901 strongly attenuated the HRG-induced increase in cellular 
migration, demonstrating a pro-migratory role of HRG-induced Erk signaling 
(Fig.22C). The pro-migratory effect of HRG was further examined during a single cell 
motility assay. In this assay, MCF7 cells were seeded at low density on fibronection-
coated surfaces, followed by live-cell time-lapse imaging to track individual cells upon 
EGF or HRG treatment (Fig.22D, E). In agreement with our previous observations, 
HRG stimulation promoted a strong increase in cellular motility, leading to a 
significant increase in average cell migration distance, velocity and displacement, as 
compared to EGF or non-treated control cells (Fig.22F). Comparison of the 
directionality (displacement/distance) did not reveal any significant differences 
throughout the different conditions, indicating HRG does not affect the intrinsic 
persistence of migration. 
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Figure 22. HRG stimulation promotes cellular motility in an Erk dependent-manner. (A) 
Phase contrast images of MCF7 cells following removal of the 2-well culture-insert for the 
indicated times upon stimulation with 100 ng/ml EGF or HRG and non-treated control cells 
(DMEM). Scale bars = 50 µm. (B) Quantification of the edge migration of MCF7 cells upon 
stimulation with EGF or HRG and non-treated control cells (DMEM) (means ± s.e.m. n = 5). (C) 
Quantification of the edge migration of PD03 (10 uM, 1 h) pretreated and non-treated MCF7 cells 
following stimulation with 100 ng/ml HRG (means ± s.e.m. n = 3). (D) Trajectories of single MCF7 
cells following stimulation with 100 ng/ml EGF or HRG and non-treated control cells (DMEM) 
plotted with a common origin (10 cells/condition). (E) Schematic representation of quantified 
migration properties. (F) Quantifications of migration distance, velocity, displacement and 
directionality of single MCF7 cells following stimulation with 100 ng/ml EGF or HRG and non-
treated control cells (means ± s.d., n = 210 - 233 cells/condition from three independent 
experiments). Statistical significance was determined using an ordinary one-way ANOVA followed 
by Tukey’s multiple comparison test (****, p > 0.0001; ***, p > 0.001; **, p > 0.01). 
Phosphorylation of the cell guidance receptor EphA2 on serine 897 (S897) enhances 
cell migration/invasion, whereas ligand-dependent EphA2 activation suppresses cell 
migration127,128. Modulating the balance between ligand-dependent and ligand-
independent EphA2 signaling thereby can have profound effects on cellular motility. 
In agreement with the positive effect of HRG on cellular motility, we observed a 
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strong increase of S897 phosphorylation in response HRG as compared to EGF 
stimulation (Fig.23A, B). HRG-induced phosphorylation of S897 was strongly 
attenuated upon Mek inhibition, demonstrating the requirement of Erk activity for 
S897 phosphorylation. Erk can further promote cellular movement through 
phosphorylation of various effector molecules involved in the regulation of the 
cytoskeletal machinery, such as the WAVE Regulatory Complex (WAVE2) or the 
focal adhesion adaptor protein Paxillin129. We observed a strong mobility shift of the 
WAVE2 and Paxillin protein bands upon HRG stimulation, indicative of their 
respective active states, as compared to EGF stimulation, which was reduced upon 
Mek inhibition (Fig.23C). Collectively, these findings imply, that HRG-induced Erk 
activity promotes migration via phosphorylation of different effector molecules, 
necessary for cellular motility. This direct role of Erk signaling in cell motility is 
strongly supported by previous studies, which reported that activated Erk localizes to 
cell protrusions and cell-matrix adhesion sites129,130. The spatial confinement of active 
Erk to membrane-proximal regions might provide a mechanism to affect the local 
state of the cytoskeleton, via the targeted phosphorylation of migratory effectors at 
the PM such as S897 of EphA2. To control the subcellular localization of Erk activity, 
we constructed membrane-targeted (GFP-Erk2-CA-tKRas) or “soluble” (GFP-Erk2-
CA) Erk proteins containing L73P and S151A substitutions, which promote enhanced 
Erk2 autophosphorylation as compared to wild type Erk2 (Fig.23D, E). Despite 
similar phosphorylation levels, localization of active Erk to the cytosol did not affect 
the phosphorylation of S897 of EphA2, while membrane-targeted Erk significantly 
enhanced S897 phosphorylation (Fig.23E). Phosphorylation of S897 therefore 
depends on Erk activity in membrane-proximal regions. Collectively, our findings 
imply that HRG-induced, membrane-proximal Erk activity promotes the 
phosphorylation different effector molecules involved in the regulation of the 
cytoskeletal machinery, to confer a motile phenotype. 
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Figure 23. Membrane proximal Erk signaling promotes phosphorylation of S897 of EphA2. 
(A) Lysates of MCF7 cells following stimulation with 100 ng/ml EGF or HRG for the indicated 
times upon pretreatment with DMSO or PD03 (1 uM, 1h) were immunoblotted and probed for 
anti-pS897, anti-EphA2, anti-pErk and anti-Erk. (B) Quantification of S897 phosphorylation 
normalized to 60 min HRG stimulation (means ± s.e.m., n = 2). (C) Lysates of MCF7 cells 
following stimulation with 100 ng/ml EGF or HRG for 60 min upon pretreatment with DMSO or 
PD03 (1 uM, 1h) were immunoblotted and probed for anti-WAVE2, anti-Paxillin. Green arrows 
indicate gel shift of the phosphorylated fractions. (D) Fluorescence images of MCF7 cells 
expressing eGFP-Erk2 (left), eGFP-Erk2-L73P/S151D (middle, GFP-Erk2-CA), eGFP-Erk2-
L73P/S151D-tKRas (right, GFP-Erk2-CA-tKRas). Scale bars = 10 µm. (E) Lysates of MCF7 cells 
expressing eGFP-Erk2 (WT), eGFP-Erk2-L73P/S151D (CA) or eGFP-Erk2-L73P/S151D-tKRas 
(CA-tKRas) were immunoblotted and probed for anti-pS897, anti-EphA2, anti-pErk and anti-Erk 
(left) and the phosphorylation of eGFP-Erk2 variants (middle) and S897 of EphA2 (right) was 
quantified (means ± s.e.m., n = 3). Statistical significance was determined using a one-way 
ANOVA with Dunnett’s post-hoc test. 
Since KSR proteins facilitate Erk activation at the plasma membrane, we 
hypothesized, that active Erk in association with KSR might form a membrane-
associated signaling complex, which facilities cellular motility. We therefore assessed 
the effects of KSR knockout on cellular motility as described above using a 2-well 
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culture-insert to create a defined cell-free area (Fig.22A). Unstimulated control cells 
showed slightly elevated levels of cell migration upon KSR knockout, as compared to 
wild type MCF7 cells (Fig.24A). Unexpectedly, KSR knockout clones further showed 
a clear migratory response upon EGF stimulation, as compared to wild type MCF7 
cells. In, contrast, upon HRG stimulation both clones showed reduced levels of cell 
migration, during the first six hours of migration and similar levels of migration at later 
time points (Fig.24A). Cell migration can broadly be grouped into two modes: single 
cell migration and collective cell migration, with cells moving individually or as an 
assembly of multiple cells, respectively131. During our experiments we noticed, that 
KSR knockout cells showed less collective cell migration, but enhanced cell-cell 
dissociation, scattering and migration of individual cells (Fig.24B). In agreement with 
this notion we observed enhanced migration distances of individual MCF7 cells 
throughout all conditions upon KSR knockout, as compared to wild type MCF7 cells 
(Fig.24C). However, KSR knockout cells displayed significantly less intrinsic directed 
migration (Fig.24D). Together these findings imply, that KSR is involved in the 
regulation of coordinated and directed movement of collectively migrating cells, but 
lowers the migratory behavior of single cells. 
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Figure 24: Effect of KSR knockout on cell migration. (A) Quantification of the edge migration 
of wild type MCF7 (WT) or MCF7 KSR knockout cells (Clone1/2) in the absence of growth factors 
(DMEM, left) and upon stimulation with 100 ng/ml EGF (middle) or HRG (right). Means ± s.e.m. 
from three independent experiments for MCF7 KSR knockout cells. Data of wild type MCF7 cells 
were previously shown in (Fig.22A). (B) Phase contrast images of wild type MCF7 (WT) or MCF7 
KSR knockout cells (Clone1/2) following removal of the 2-well culture-insert for the indicated 
times upon stimulation with 100 ng/ml EGF for the indicated times. Arrows indicate areas of 
collectively migrating cells (red arrows) and single cells (green arrows). Scale bars = 50 µm. (C) 
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and (D) Quantifications of migration distances (C) and directionality (D) from single cell 
trajectories of wild type MCF7 (WT) or MCF7 KSR knockout cells (Clone1/2) in the absence of 
growth factors (DMEM, left) and upon stimulation with 100 ng/ml EGF (middle) or HRG (right). 
Means ± s.d., n = 163 - 252 cells/condition from three independent experiments. Data of wild type 
MCF7 cells were previously shown in (Fig.22F). Statistical significance was determined using an 
ordinary one-way ANOVA followed by Tukey’s multiple comparison test (****, p > 0.0001). 
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5 Discussion 
In this thesis, we examined how vesicular trafficking dynamics regulate the 
distribution of ErbB receptors between the plasma membrane and different 
endosomal compartments to enable contextual regulation of receptor activity and 
signaling.  
5.1 Spatial regulation of EGFR activity by vesicular trafficking 
In the first part we examined the role of EGFR vesicular dynamics in the regulation of 
autonomous receptor activity and how endosomal trafficking differentially controls the 
activity of autonomously and ligand-activated EGFR. The canonical scheme of EGFR 
activation describes ligand-induced dimerization, followed by allosteric activation of 
its intrinsic kinase activity and trans-autophosphorylation19. However, the collective 
response properties of EGFR emerge from its autocatalytic activation, coupled to 
local PTP inhibition at the plasma membrane, establishing a bistable reaction 
network with switch like response properties41,46. Analogous to a toggle switch, this 
reaction network converts growth factor stimuli into threshold-activated, but on the 
other hand creates the potential to amplify spontaneous phosphorylation events even 
in the absence of growth factors responses41,50. Therefore, regulatory mechanisms 
are required to control autonomous autocatalytic EGFR activity. We identified how 
the coupling of EGFR self-association state, ubiquitination and vesicular dynamics 
allows for the coexistence of a continuous safeguard cycle, to maintain low EGFR 
phosphorylation at the PM, while preserving sensitivity to growth factor stimulation. 
5.1.1 Autonomous activation of EGFR in the absence of ligand 
Recent studies reported that EGFR can also be activated in the absence of ligand at 
high surface densities36,132. Despite steric auto-inhibitory features, a subpopulation of 
EGFR can adopt an active conformation in the absence of ligand, due to thermal 
conformational fluctuations43,133. We investigated the extent of autonomous 
phosphorylation of three tyrosine residues that possess different regulatory functions, 
of autocatalysis (Y845), trafficking (Y1045), and signaling (Y1068) as a function of 
EGFR expression (Fig.7A, Fig.8A). The extent of ligand independent activation for 
all three sites increased with the expression of the receptor (Fig.7B, Fig.8B). Y845 
and Y1068 showed significantly higher levels of autonomous phosphorylation as 
compared to Y1045 (Fig.7C, Fig.8C). Phosphorylation of Y1045 creates a docking 
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site for the E3-ubiquitin ligase c-Cbl, thereby functioning as an important determinant 
regulating the trafficking of the receptor. The low efficiency of autonomous Y1045 
phosphorylation potentially avoids receptor ubiquitination and degradation in the 
absence of ligand. A recent study revealed that trans-phosphorylation of Y845 can 
stabilize monomeric EGFR in an active conformation, promoting autocatalytic 
amplification of its activity43. Tight regulation of the Y845 phosphorylation status is 
therefore essential to avoid its spontaneous phosphorylation and autocatalytic 
amplification of EGFR activation, which otherwise would result in uncontrolled 
receptor phosphorylation in the absence of ligand. Consistent with this notion, Y845 
phosphorylation was most efficiently suppressed by phosphatases in the absence of 
ligand as compared to Y1045 and Y1068 (Fig.9C). 
Autonomously activated and ligand-activated receptors differed with regard to their 
self-association state and their capability to engage downstream signaling molecules 
(Fig.10). High levels of autonomous EGFR phosphorylation were found to promote 
the phosphorylation of Akt (Fig.10B, E). The activation of Akt promotes vesicular 
recycling of EGFR to increase its abundance at the plasma membrane, effectively 
generating a positive feedback due to the autocatalytic nature of EGFR 
phosphorylation66, which might further increase the propensity for autonomous 
activation. Interestingly, the phosphorylation of Erk remained unresponsive to 
autonomous receptor activation (Fig.10B, E), implying negative feedbacks within the 
Erk circuity conferring robustness to EGFR expression levels or inefficient coupling 
between autonomously activated EGFR to Erk at the plasma membrane, as 
compared to internalized endosomal EGFR132,134,135. 
5.1.2 Continuous vesicular recycling suppresses autonomous EGFR 
activation 
Autocatalytic amplification of EGFR activity can result in uncontrolled receptor 
activation and signaling, even in the absence of ligand, necessitating regulatory 
mechanisms to counteract autonomous receptor activation at the plasma membrane. 
We addressed whether the endocytic machinery contributes to the regulation of 
autonomous phosphorylation of unliganded receptors. Vesicular membrane 
dynamics allow the cell to regulate the spatial distribution of cell surface receptors 
between the plasma membrane and different endosomal compartments that are rich 
in suppressive phosphatase activity. It was observed that, in the absence of ligand, 
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EGFR continuously cycles between the plasma membrane (PM) and Rab11-positive 
perinuclear recycling endosomes (RE) (Fig.11, Fig.12). Alterations in the vesicular 
recycling of EGFR using genetic perturbations of Rab11, influenced the magnitude of 
EGFR activation in the absence of EGF (enhanced and decreased receptor 
phosphorylation upon Rab11 knockdown and overexpression, respectively (Fig.13D, 
F, H). These findings suggest that a continuous vesicular recycling of EGFR through 
this compartment regulates the autonomous phosphorylation of unliganded 
receptors. Previous work established that the activity of the endoplasmic reticulum-
anchored phosphatase PTP1B is highest on perinuclear membranes and PTP1B-
catalyzed dephosphorylation of EGF-bound EGFR requires receptor endocytosis of 
the receptor59,78. In agreement with these findings, the spatially distributed interacting 
fraction displayed an interaction between EGFR and PTP1B in the perinuclear area 
(Fig.14E). Considering that the catalytic activity of fully active PTPs (e.g. PTP1B or 
TCPTP) exceeds the catalytic activity of EGFR by up to two orders of magnitude, the 
spatial segregation of catalytically superior PTPs from EGFR is a prerequisite to 
permit growth factor induced receptor activation at the plasma membrane (Fig.14F, 
H)56–58. Our results show that continuous vesicular recycling of EGFR in the absence 
of ligand between the PM and RE promotes the interaction with the ER-localized 
PTP1B and thereby counteracts autonomous receptor activation to maintain low 
levels of EGFR phosphorylation at the PM. The spatial separation of EGFR activity at 
the plasma membrane and PTP activity at the perinuclear area provides a system 
which safeguards against autonomous receptor activation at the PM and maintains 
cellular responsiveness to both new and sustained stimuli by regulating PM EGFR 
abundance. 
5.1.3 A ubiquitin mediated switch in vesicular trafficking 
Constitutive vesicular recycling of EGFR suppresses autonomous receptor activation, 
while maintaining a growth factor responsive receptor population at the plasma 
membrane (Fig.25). EGF stimulation results in enhanced receptor internalization, 
promoting receptor inactivation via ER-associated PTPs, followed by either 
endosomal-plasma membrane recycling or lysosomal degradation67,77,78. In order to 
identify the decisive factor that determines the fate of the receptor between these 
distinct trafficking routes, we compared the vesicular trafficking of PV-mediated, 
autonomously activated and EGF-activated receptors (Fig.15D). Autonomously 
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activated receptors continued to cyclically traffic via the Rab11-positive RE, while 
EGF stimulation recruited c-Cbl to EGFR positive endosomes, redirecting the 
receptor towards lysosomal degradation (Fig.15E). Despite high levels of Y1045 
phosphorylation, autonomously activated EGFR was inefficiently ubiquitinated and 
degraded (Fig.15B, C). These findings imply that Y1045 is not sufficient to trigger c-
Cbl mediated receptor ubiquitination and thereby switch receptor trafficking from 
vesicular recycling to lysosomal degradation. Since EGF stimulation also promotes 
enhanced receptor self-association (Fig.10F), EGFR ubiquitination forms a 
secondary signal that relies on both the phosphorylation of Y1045 and the formation 
of EGFR oligomers. A ubiquitin-deficient EGFR mutant continued to recycle via the 
RE after ligand stimulation, resulting in a sustained phosphorylation response 
(Fig16A, C). These findings demonstrate that redirecting vesicular trafficking towards 
lysosomal degradation to is necessary impose a finite signaling response, since 
recycling of EGF-EGFR complexes would consequently result in sustained receptor 
reactivation at the plasma membrane. Recent studies showed that receptor 
ubiquitination upon EGF-stimulation follows a threshold-controlled mechanism, due to 
the cooperative recruitment of c- Cbl, in complex with Grb2, resulting inefficient 
receptor ubiquitination at low EGF concentrations73. Hence vesicular recycling of the 
receptor is the preferential trafficking route in response to subsaturating EGF 
concentrations, which maintains the sensitivity of the cell to persistent stimulation, 
whereas at saturating EGF doses ubiquitin-dependent lysosomal degradation of 
EGFR generates a finite signaling response66,71,72. Inefficient receptor degradation 
due to mutation or overexpression of EGFR and c-Cbl mutations, resulting in 
prolonged receptor activation, has further been implicated in human disease136–138. 
Our findings show that autonomously activated and EGF activated receptors are 
processed differently by the endocytic machinery (Fig.25). Receptor ubiquitination 
functions as a decisive factor promoting different trafficking fates of EGFR 
(endosomal-plasma membrane recycling versus lysosomal degradation). Similar 
features have been observed for the cell guidance ephrin receptor type-A2 (EphA2), 
implying a common cellular mechanism for the regulation of RTK activity139. 
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Figure 25: Differential vesicular dynamics of autonomously activated and ligand-activated 
EGFR. Constitutive vesicular recycling of EGFR through perinuclear areas with high PTP activity 
suppresses autonomous receptor activation in the absence of ligand, while maintaining a growth 
factor responsive receptor population at the plasma membrane (left). EGF-induced ubiquitination 
of EGFR clusters switches vesicular trafficking from continuous recycling towards lysosomal 
degradation, thereby imposing a finite signaling response (right). 
5.2 Ligand-specific ErbB receptor trafficking determines Erk signaling 
specificity 
In the second part of this thesis we examined how the spatial and temporal 
distribution of active ErbB receptors within the endosomal system determines the 
spatiotemporal organization of Erk signaling. Different ErbB ligands have been 
shown to induce distinct temporal patterns of Erk activation, which were linked to 
different cellular fates105. However, if different growth factors modulate Erk signaling 
in a spatially dependent fashion, to control cellular responses remains unclear. We 
show that EGF or heregulin (HRG) differentially modulate ErbB receptor trafficking to 
generate distinct spatiotemporal patterns of receptor activities, leading to the 
activation of Erk from different subcellular compartments (plasma membrane and 
endosomes). The subcellular localization of Erk activation influences its interaction 
with different effector proteins and thereby generates different cellular responses. 
Suppression of
autonomous activation Ligand activation
EGF
PTP1B
Low High
RT
K 
ph
os
ph
or
yl
at
io
n
LowHigh
PT
P 
ac
tiv
ity
Rab11
RE
EE
EE
EE
Rab5
Lysosome
Phosphotyrosine
Ubiquitin
EGFR EGFRp 
EGFR 
PTP
EGFRp 
EGFR 
PTP
EGFRp 
EGFR* EGFR
1045
1068
1045
1068
845
Cbl
 80 
5.2.1 EGF and HRG promote Erk activation from different subcellular locations 
Stimulation of the human breast cancer cell line MCF7 with EGF or HRG promotes 
transient or sustained activation of Erk, respectively (Fig.17A). Furthermore, we find 
that these growth factors further promote the activation of Erk from distinct 
subcellular localizations (endosomes and PM, respectively) (Fig.19). These 
differences in the spatial dynamics of Erk activation are the result of differences in 
vesicular trafficking, and, consequently, the localization of active ErbB receptors 
following EGF or HRG stimulation. As described previously, EGF stimulation 
promotes the internalization and ubiquitination of EGFR, leading to lysosomal 
degradation and transient, receptor activity (Fig.18, 19A). In contrast, following HRG 
stimulation, active ErbB2/3 receptors remain predominantly at the plasma membrane, 
generating a persistent Erk response from this compartment (Fig.18, 19A). This 
differential receptor trafficking has important implications on cellular behavior, as the 
signaling repertoire of endosomal and plasma membrane localized receptors can 
differ if biochemical components of the signal transduction machinery are not equally 
accessible in these distinct subcellular compartments. Rapid internalization of EGFR 
following EGF stimulation limits its capacity to efficiently induce the production of 
PIP3 at the plasma membrane and engage Akt signaling (Fig.19B, D). However, 
internalized EGFR can continue to activate signaling effectors such as Erk from 
endosomal membranes, resulting in comparable amplitudes of Erk phosphorylation 
between both growth factors (Fig.17A, Fig.19D). Modulating EGFR trafficking by 
different types of context, such as ligand concentration, ligand identity or cell-cell 
contacts can generate considerable plasticity in EGFR function to alter cellular 
behavior. The dichotomy between lysosomal degradation and recycling, for example, 
determines signaling duration72,140. Furthermore, a recent study revealed that cell-cell 
interactions can alter the spatial distribution of EGFR activity, thereby selectively 
suppressing pro-migratory receptor signaling from the plasma membrane, while 
preserving proliferative endosomal signaling66. Similar relationships, have also been 
reported for other RTKs, such as PDGFR or Met141,142. In contrast, the spatial 
confinement of the active ErbB2/3 heterodimer to the plasma membrane could 
potentially limit its functional plasticity, as compared to receptor systems, that 
possess tunable vesicular dynamics. As various different receptor molecules can 
elicit similar cellular behaviors within a given cellular system, it seems plausible, that 
cellular responses to ErbB receptor activation are governed by the context-
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dependent spatiotemporal distribution of active receptors rather than relying solely on 
their molecular identity. 
5.2.2 KSR enhances Erk activation at the PM 
Scaffold proteins can assemble multiprotein complexes to coordinate Erk activation 
from various subcellular localizations (e.g. PM, endosomes, golgi, nucleus)124. Using 
CRISPR-Cas9 genome editing, to knockout the plasma membrane scaffolds KSR1/2, 
we find that KSR knockout specifically attenuated HRG-induced Erk phosphorylation 
and signaling, while EGF-induced Erk phosphorylation was not affected. The 
contrasting effects of KSR knockout on the EGF- versus or HRG-induced Erk 
signaling are the result of the different spatiotemporal patterns of ErbB activity 
generated by these ligands (PM versus endosomes). On the other hand, EGF-
induced endosomal Erk signaling might be facilitated by an endosomal scaffold 
protein, such as MP1143. The local confinement of Erk activity towards subcellular 
structures and the cytosolic localization of inactivating phosphatases have further 
been suggested to generate spatial gradients of Erk activity5,144. The signal-
dependent localization of Erk activity to distinct subcellular localizations via scaffold 
proteins could thereby provide a mechanism to direct Erk activity towards specific 
local pools of substrates104. Aside from the localization and the physical assembly of 
molecular components, scaffold proteins can further generate diverse functions by 
insulating signaling modules or the direction of feedback regulation145. A recent study 
revealed that the input sensitivity of the Erk module is determined by its subcellular 
location146. At the plasma membrane, the Erk module is sensitive to low-level input, 
whereas the threshold for activation is high in the cytosol. At the plasma membrane 
KSR might thereby not only influence the amplitude of Erk activity, but also determine 
the sensitivity of the module towards different ligand concentrations. 
5.2.3 EGF and HRG promote Erk-dependent cell proliferation 
Differences in the spatial and temporal organization of signaling molecules plays a 
key role modulating their context-dependent function, thereby ultimately controlling 
cellular responses. The different spatial organization of ErbB receptor kinase activity 
in response to EGF and HRG stimulation were found to promote the activation of Erk 
from different subcellular compartments (endosomes and plasma membrane, 
respectively). We assessed whether these differences in the spatial dynamics of Erk 
correlate with different cellular outcomes. EGF and HRG induced a similar, Erk-
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dependent increase in cellular proliferation (Fig.21). In agreement with this notion, it 
was previously reported, that both ligands induce transient nuclear Erk activity, while 
HRG additionally promotes sustained cytoplasmic Erk activity107. The transient 
nuclear Erk activity upon HRG stimulation was explained due to an elevated 
expression of nuclear localized dual specific phosphatases (DUSPs), inactivating Erk 
in the nucleus over time107. Comparable nuclear activity of Erk in response to HRG 
and EGF, might therefore account for the similar increase in cellular proliferation. 
Furthermore, previous studies identified, distinct periods of competency for cell-cycle 
induction by Erk147,148. Such a process might further restrain the ability of different Erk 
kinetics (transient versus sustained) to prime different populations of cells for cell-
cycle progression, resulting in comparable levels of proliferation within the observed 
time frame (24 h). Furthermore, our findings imply that proliferative Erk signals are 
transmitted to the nucleus, irrespective of their spatial origin (endosomes and plasma 
membrane, respectively). 
5.2.4 Membrane proximal Erk signaling promotes cellular motility  
Directional cellular movement requires cells to remain responsive to the 
chemoattractant for prolonged periods of times. Accumulating evidence suggests that 
HRG ligands promote tumorigenesis of breast cancer cells by increasing both, 
cellular proliferation and invasion149,150,151. In agreement with this, we observe that 
persistent plasma membrane receptor activity upon HRG stimulation, correlates with 
enhanced cellular motility, as compared to finite EGFR signaling upon EGF 
stimulation (Fig.22B, F). Single cell measurements further indicated, that HRG 
increases the overall cellular motility rather than affecting the intrinsic persistence of 
migration (Fig.22F). This HRG-induced increase in cellular motility was dependent on 
Erk activity, as Mek inhibition, strongly attenuated cellular migration (Fig.22C). 
Consistent with this notion, we observed the Erk-dependent phosphorylation of 
various effector molecules involved in the regulation of cellular motility in response to 
HRG stimulation, but not upon EGF stimulation (Fig.23A, E). In addition to the 
temporal regulation of Erk activity, the spatial organization of ErbB kinase activity 
may further enable the cell to generate different pools of active Erk with distinct 
functionality (transcriptional activity in the nucleus and local morphogenetic function 
at the plasma membrane). Such a dual functionality has been suggested for the 
mating-pheromone MAPK cascade in yeast, in which membrane proximal activity of 
 83 
the MAPK Fus3 locally affects cytoskeletal structures, whereas in the nucleus it 
affects gene expression46,152. In agreement with this, we found that pro-migratory 
phosphorylation of EphA2 on serine 897 (S897), relies on membrane proximal Erk 
activity (Fig.23A, C). In previous studies, phospho-S897-EphA2 was found to localize 
to the leading edge of migrating cells, promoting the assembly of actin cytoskeleton 
and extension of lamellipodia127. Localized phosphorylation of S897 might thereby 
provide a mechanism to promote cell motility in a spatially controlled manner. In 
addition to membrane proximal Erk signaling, the HRG-induced pro-migratory 
behavior is most likely further facilitated by the activation plasma membrane signaling 
events, such as PIP3 production and Akt activation (Fig.19B, E). 
To test whether the plasma membrane scaffold KSR contributes to cellular migration, 
the migratory behavior of KSR1/2 knockout cells was examined. Knockout of KSR1/2 
enhanced the motility of individual cells but reduced their intrinsic directionality and 
further the coordinated movement of cell groups during collective migration (Fig.24). 
KSR proteins might therefore exert a dual role regarding cellular migration, by 
reducing the overall motility of single cells to allow for the maintenance of cell-cell 
contacts and thereby enhance the efficiency of collective cellular movement. 
Furthermore, KSR1/2 knockout cells displayed a strong migratory response upon 
EGF stimulation, as compared to wild type cells. In this regard, it could be 
speculated, that the knockout of KSR causes the loss of an Erk-mediated negative 
feedback, such as phosphorylation of Thr669 in the juxtamembrane segment of 
EGFR and thereby enhances the overall activity of EGFR153. However, in addition to 
their interactions with components of the MAPK cascade, KSR proteins have been 
shown to interact with a multitude of other signaling molecules154. In this regard, 
pleiotropic effects on a complex cellular phenotype such as migration, due to chronic 
genetic perturbations could not be excluded. 
Collectively our findings suggest that the confinement of active Erk to membrane 
proximal regions is a possible means to promote cellular motility, as pro-migratory 
phosphorylation of the EphA2 S897 was dependent on the presence of membrane 
proximal Erk activity (Fig.23E). In contrast, proliferative Erk signals are transmitted to 
the nucleus, irrespective of their spatial origin (Fig.26). Differences in the spatial 
distribution of active ErbB receptors due to different vesicular trafficking determine 
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the spatial distribution of Erk activity and thereby modulate its interaction with 
different pools of substrates to generate different cellular responses. 
 
Figure 26: EGF-and HRG-induced ErbB/Erk dynamics. EGF and HRG promote the activation 
of Erk from distinct subcellular localizations (endosomes and PM, respectively). Proliferative Erk 
signals are transmitted to the nucleus, irrespective of their spatial origin, while HRG-induced 
membrane proximal Erk signaling promotes the phosphorylation of migratory effectors such as 
S897 of EphA2. 
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7 Abbreviations 
°C    Degree Celsius 
a.u.    Arbitrary units 
Akt/PKB   Protein kinase B 
ANOVA   Analysis of variance 
ATP    Adenosine triphosphate 
BFP    Blue fluorescent protein 
C-terminus   Carboxyl terminus 
CRISPR Clustered Regularly Interspaced Short Palindromic 
Repeats 
DMEM   Dulbecco’s modified eagle medium 
DNA    Deoxy ribonucleic acid 
DTT    Dithiothreitol 
DUSP    Dual-specificity phosphatase 
EDTA    Ethylene diamine tetraacetic acid 
EE    Early endosomes 
EGF    Epidermal growth factor 
eGFP    Enhanced green fluorescent protein 
EGFR    Epidermal growth factor receptor 
EphA2    Ephrin receptor type-A2 
ER    Endoplasmatic reticulum 
Erk    extracellular signal-regulated kinase 
FBS    Fetal bovine serum  
Fig.    Figure 
FLIM    Fluorescence lifetime imaging microscopy 
FRET    Förster resonance energy transfer 
GEF    Guanine nucleotide exchange factors 
GTP    Guanosine-5'-triphosphate 
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h    Hour 
HRG    Heregulin 
IP    Immunoprecipitation 
kB    Kilo base pair 
LAMP1   Lysosomal-associated membrane protein 1 
LE    Late endosome 
m    Meter 
MAPK    Mitogen-activated protein kinase 
MAPKK   Mitogen-activated protein kinase kinase 
MAPKKK   Mitogen-activated protein kinase kinase kinase 
mCherry   monomeric Cherry 
mCitrine   monomeric Citrine 
Min    Minute 
ml    Milliliter 
mM    Millimolar 
n    Nano 
N-Terminus   Amino-terminus 
NA    Numerical aperture 
NEAA    Non-essential amino acids 
ng    Nanogram 
NGF    Nerve growth factor 
PAGE    polyacrylamide gel electrophoresis 
PBS    Phosphate buffered saline 
PCR    Polymerase chain reaction 
PD03    Mek inhibitor PD0325901 
PH    Pleckstrin homology domain 
PI3K    Phosphoinositide-3-kinase 
PIP3    Phosphatidylinositol (3,4,5)-trisphosphate 
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PM    Plasma membrane 
pRb    Phosphorylated retinoblastoma protein 
PTB    Phosphotyrosine-binding domain 
PTP    Protein tyrosine phosphatase 
PV    Pervanadate 
pY    Phospho tyrosine 
RE    Recycling endosome 
ROS    Reactive oxygen species 
RTK    Receptor tyrosine kinase 
s     Second 
s.d.    Standard deviation 
s.e.m.    Standard error of mean  
SDS     Sodium dodecyl sulphate 
SH2    Src homology 2 
siRNA    Small interfering RNA 
SOS    Son of Sevenless 
TAE    Tris-acetate-EDTA 
TBS    Tris buffered salinetKRas 
tKRas    Farnesyl tail of KRas 
Ug    Micro 
V    Volt 
WT    Wild type 
Y    Tyrosine 
µ    Micro 
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